10521294

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 3	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 4	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS 5	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS 6	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 7	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS 8	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 9	NOV 26	MARPAT enhanced with FSORT command
NEWS 10	NOV 26	MEDLINE year-end processing temporarily halts availability of new fully-indexed citations
NEWS 11	NOV 26	CHEMSAFE now available on STN Easy
NEWS 12	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 13	DEC 01	ChemPort single article sales feature unavailable
NEWS 14	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 15	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 16	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

Updated Search

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:33:13 ON 06 JAN 2009

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.22 0.22

FILE 'REGISTRY' ENTERED AT 15:33:24 ON 06 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JAN 2009 HIGHEST RN 1092651-12-1
DICTIONARY FILE UPDATES: 5 JAN 2009 HIGHEST RN 1092651-12-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\2945.str

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 15:36:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8632 TO ITERATE

23.2% PROCESSED 2000 ITERATIONS 44 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 167071 TO 178209
PROJECTED ANSWERS: 2972 TO 4624

L2 44 SEA SSS SAM L1

```
=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 15:36:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   169152 TO ITERATE

100.0% PROCESSED   169152 ITERATIONS                          3396 ANSWERS
SEARCH TIME: 00.00.01

L3         3396 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             187.80     188.02

FILE 'HCAPLUS' ENTERED AT 15:36:19 ON 06 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Jan 2009  VOL 150 ISS 2
FILE LAST UPDATED: 5 Jan 2009  (20090105/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3/uses
           543 L3
       7350115 USES/RL
L4         155 L3/USES
                (L3 (L) USES/RL)

=> s l4 and rode, b?/au
           412 RODE, B?/AU
L5           0 L4 AND RODE, B?/AU

=> s l4 and rozman, d?/au
            73 ROZMAN, D?/AU
```

L6 1 L4 AND ROZMAN, D?/AU

=> d l6, ibib abs hitstr, 1

L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:59050 HCAPLUS
DOCUMENT NUMBER: 148:321816
TITLE: Novel cholesterol biosynthesis inhibitors targeting human lanosterol 14α-demethylase (CYP51)
AUTHOR(S): Korosec, Tina; Acimovic, Jure; Seliskar, Matej; Kocjan, Darko; Tacer, Klementina Fon; Rozman, Damjana; Urleb, Uros
CORPORATE SOURCE: Drug Discovery, Lek Pharmaceuticals d. d., Ljubljana, Verovskova 57, 1000, 57, Slovenia
SOURCE: Bioorganic & Medicinal Chemistry (2008), 16(1), 209-221
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 148:321816

AB Novel cholesterol biosynthesis inhibitors, a group of pyridylethanol(phenylethyl)amine derivs., were synthesized. Sterol profiling assay in the human hepatoma HepG2 cells revealed that compds. target human lanosterol 14α-demethylase (CYP51). Structure-activity relationship study of the binding with the overexpressed human CYP51 indicates that the pyridine binds within the heme binding pocket in an analogy with the azoles.

IT 1010077-08-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel cholesterol biosynthesis inhibitors targeting human lanosterol 14α-demethylase (CYP51))

RN 1010077-08-3 HCAPLUS
CN Benzenemethanol, α-[[[2-(3,4-dichlorophenyl)ethyl]propylamino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

```
     (FILE 'HOME' ENTERED AT 15:33:13 ON 06 JAN 2009)

     FILE 'REGISTRY' ENTERED AT 15:33:24 ON 06 JAN 2009
L1             STRUCTURE UPLOADED
L2              44 S L1
L3            3396 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 15:36:19 ON 06 JAN 2009
L4             155 S L3/USES
L5               0 S L4 AND RODE, B?/AU
L6               1 S L4 AND ROZMAN, D?/AU

=> s l4 not l6
L7           154 L4 NOT L6

=> s l7 and fon tacer, k?/au
               2 FON TACER, K?/AU
L8             0 L7 AND FON TACER, K?/AU

=> s l7 and kocja, d?/au
               0 KOCJA, D?/AU
L9             0 L7 AND KOCJA, D?/AU

=> s l7 and pd < august 2002
      22821025 PD < AUGUST 2002
                 (PD<20020800)
L10           77 L7 AND PD < AUGUST 2002

=> d l10, ibib abs fhitstr, 1-77

L10  ANSWER 1 OF 77  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2006:666025  HCAPLUS
DOCUMENT NUMBER:          145:152690
TITLE:                    Method for inducing crystalline state transition in
                          pharmaceuticals
INVENTOR(S):              Nakamichi, Kouichi; Izumi, Shougo; Oka, Masaaki
PATENT ASSIGNEE(S):       Nippon Shinyaju Company, Ltd., Japan
SOURCE:                   U.S., 18 pp., Cont.-in-part of U. S. 5,456,923.
                          CODEN: USXXAM
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     US 5811547           A     19980922    US 1995-416815         19950609 <--
     CA 2147279           A1    19940428    CA 1993-2147279        19931013 <--
     WO 9408561           A1    19940428    WO 1993-JP1469         19931013 <--
         W:  AU, BR, CA, FI, HU, JP, KR, NO, NZ, RU, US
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     AU 9351607           A     19940509    AU 1993-51607          19931013 <--
     EP 665009            A1    19950802    EP 1993-922625         19931013 <--
     EP 665009            B1    20000216
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
```

AT 189770	T	20000315	AT 1993-922625	19931013 <--
ES 2145063	T3	20000701	ES 1993-922625	19931013 <--
US 5456923	A	19951010	US 1993-129133	19931115 <--
PRIORITY APPLN. INFO.:			JP 1992-303085	A 19921014
			WO 1993-JP1469	W 19931013
			US 1993-129133	A2 19931115
			JP 1991-112554	A 19910416
			WO 1992-JP470	W 19920414

AB This invention has for its object to provide a method of inducing a transition in crystalline state of a crystallizable pharmaceutical with great ease and improved efficiency and uniformity on a high production scale. An extruder is used for inducing a transition from one crystalline state (Δ) to another crystalline state in a crystallizable pharmaceutical. An extruded indomethacin (form α) was converted to an amorphous form.

IT 71771-90-9, Denopamine
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for inducing crystalline state transition in pharmaceuticals)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:319495 HCAPLUS

DOCUMENT NUMBER: 138:343864

TITLE: In vivo delivery methods and compositions

INVENTOR(S): Kensey, Kenneth

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 819,924.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030078517	A1	20030424	US 2001-839785	20010420
US 6019735	A	20000201	US 1997-919906	19970828 <--

CA 2301161 A1 19990304 CA 1998-2301161 19980826 <--
WO 9910724 A2 19990304 WO 1998-US17657 19980826 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
HU 2001000201 A2 20010528 HU 2001-201 19980826 <--
HU 2001000201 A3 20040329
NZ 502905 A 20010831 NZ 1998-502905 19980826 <--
JP 2001514384 T 20010911 JP 2000-507994 19980826 <--
US 6322524 B1 20011127 US 1999-439795 19991112 <--
US 6322525 B1 20011127 US 2000-501856 20000210 <--
NO 2000000944 A 20000225 NO 2000-944 20000225 <--
MX 200002073 A 20010821 MX 2000-2073 20000228 <--
US 6428488 B1 20020806 US 2000-615340 20000712
WO 2002009583 A2 20020207 WO 2001-US23696 20010730 <--
WO 2002009583 A3 20020425
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002043806 A2 20020606 WO 2001-US44352 20011127 <--
WO 2002043806 A3 20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002026986 A 20020611 AU 2002-26986 20011127 <--
US 20020088953 A1 20020711 US 2001-33841 20011227 <--
US 6624435 B2 20030923
WO 2002079778 A2 20021010 WO 2002-US3984 20020207
WO 2002079778 A3 20030710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20020184941	A1	20021212	US 2002-156165	20020528
US 6571608	B2	20030603		

PRIORITY APPLN. INFO.:

US 1997-919906	A2 19970828
US 1999-439795	A2 19991112
US 2000-501856	A2 20000210
US 2000-628401	A2 20000801
US 2000-727950	B2 20001201
US 2001-819924	A2 20010328
US 1997-966076	A 19971107
WO 1998-US17657	W 19980826
US 2000-615340	A3 20000712
US 2000-228612P	P 20000828
US 2001-789350	B2 20010221
US 2001-828761	A 20010409
US 2001-839785	A 20010420
US 2001-841389	A 20010424
US 2001-897164	A3 20010702
WO 2001-US44352	W 20011127

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least 1 drug. Agents effective to regulate at least 1 of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

IT 128470-16-6, Arbutamine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vivo delivery methods and compns.)

RN 128470-16-6 HCAPLUS

CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 3 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:32015 HCAPLUS
DOCUMENT NUMBER: 138:82843
TITLE: Denopamine, a selective β1-receptor agonist and a

	new coronary vasodilator
AUTHOR(S):	Ishide, Takeshi
CORPORATE SOURCE:	Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chuou-ku, Chiba, 260-8670, Japan
SOURCE:	Current Medical Research and Opinion (2002), 18(7), 407-413 CODEN: CMROCX; ISSN: 0300-7995
PUBLISHER:	LibraPharm Ltd.
DOCUMENT TYPE:	Journal; General Review
LANGUAGE:	English

AB A review. Up until now, it has been suggested that nitrate and/or calcium channel blockers were effective against variant angina pectoris. On the other hand, it is known that about 20% of variant angina pectoris was refractory to both nitrate and calcium channel blockers. In Japan, it has been reported that denopamine, which is an oral β1-adrenoceptor selective agonist developed by the Japanese pharmaceutical industry (Tanabe Seiyaku), is effective in those refractory cases. To date, in Japan nine cases have been recognized of patients with vasospastic angina pectoris whose symptoms were relieved by taking denopamine, including one case in which the author has had personal experience. Eight of these nine cases were refractory, and were not relieved by combined therapy using both nitrate and a calcium channel blocker. It was also documented that denopamine was effective in cases where attacks were not relieved by prazosin or magnesium, which have been documented as effective in other refractory cases. In a study of canine coronary arteries, localization of β-adrenoceptor subtypes was documented, with the β1-adrenoceptor predominantly found in the conduit coronary artery. In recent years it has been emphasized that the principal role of sympathetic nerves was not associated with the constrictive action of α-adrenoceptors, but with the coronary dilative action of β-adrenoceptors. It would therefore be worthwhile to determine whether denopamine is able to relieve vasospastic angina pectoris in many more cases.

IT 71771-90-9, Denopamine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(denopamine, β1-receptor agonist and new coronary vasodilator, for angina pectoris)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:428760 HCAPLUS
DOCUMENT NUMBER: 137:24314
TITLE: Methods and apparatus for determining and utilizing the viscosity of circulating blood over a range of shear rates for diagnostics and treatment
INVENTOR(S): Kensey, Kenneth; Hokanson, Charles
PATENT ASSIGNEE(S): Visco Technologies, Inc., USA; Rheologics, Inc.
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002043806	A2	20020606	WO 2001-US44352	20011127	<--
WO 2002043806	A3	20030327			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2301161	A1	19990304	CA 1998-2301161	19980826	<--
WO 9910724	A2	19990304	WO 1998-US17657	19980826	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
HU 2001000201	A2	20010528	HU 2001-201	19980826	<--
HU 2001000201	A3	20040329			
NZ 502905	A	20010831	NZ 1998-502905	19980826	<--
JP 2001514384	T	20010911	JP 2000-507994	19980826	<--
NO 2000000944	A	20000225	NO 2000-944	20000225	<--
US 20020061835	A1	20020523	US 2001-828761	20010409	<--
US 20030078517	A1	20030424	US 2001-839785	20010420	
AU 2002026986	A	20020611	AU 2002-26986	20011127	<--
PRIORITY APPLN. INFO.:			US 1997-966076	A 19971107	
			US 2000-727950	A 20001201	
			US 2001-819924	A 20010328	
			US 2001-828761	A 20010409	
			US 2001-839785	A 20010420	
			US 1997-919906	A 19970828	

WO 1998-US17657	W	19980826
US 1999-439795	A2	19991112
US 2000-501856	A2	20000210
US 2000-628401	A2	20000801
WO 2001-US44352	W	20011127

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

IT 128470-16-6, Arbutamine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and apparatus for determining and utilizing the viscosity of circulating
blood over a range of shear rates for diagnostics and treatment)

RN 128470-16-6 HCAPLUS

CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2002:392219 HCAPLUS
DOCUMENT NUMBER:	136:406945
TITLE:	Methods for in vivo drug delivery based on monitoring blood flow parameters
INVENTOR(S):	Kensey, Kenneth R.
PATENT ASSIGNEE(S):	USA
SOURCE:	U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 727,950. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20020061835	A1	20020523	US 2001-828761	20010409	<--
US 6019735	A	20000201	US 1997-919906	19970828	<--
CA 2301161	A1	19990304	CA 1998-2301161	19980826	<--
WO 9910724	A2	19990304	WO 1998-US17657	19980826	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
HU 2001000201	A2	20010528	HU 2001-201	19980826	<--
HU 2001000201	A3	20040329			
NZ 502905	A	20010831	NZ 1998-502905	19980826	<--
JP 2001514384	T	20010911	JP 2000-507994	19980826	<--
US 6322524	B1	20011127	US 1999-439795	19991112	<--
US 6322525	B1	20011127	US 2000-501856	20000210	<--
NO 2000000944	A	20000225	NO 2000-944	20000225	<--
MX 200002073	A	20010821	MX 2000-2073	20000228	<--
US 6428488	B1	20020806	US 2000-615340	20000712	
WO 2002009583	A2	20020207	WO 2001-US23696	20010730	<--
WO 2002009583	A3	20020425			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
WO 2002043806	A2	20020606	WO 2001-US44352	20011127	<--
WO 2002043806	A3	20030327			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002026986	A	20020611	AU 2002-26986	20011127	<--
US 20020088953	A1	20020711	US 2001-33841	20011227	<--
US 6624435	B2	20030923			
WO 2002079778	A2	20021010	WO 2002-US3984	20020207	
WO 2002079778	A3	20030710			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,					

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

US 20020184941	A1	20021212	US 2002-156165	20020528
US 6571608	B2	20030603		

PRIORITY APPLN. INFO.:

US 1997-919906	A2 19970828
US 1999-439795	A2 19991112
US 2000-501856	A2 20000210
US 2000-628401	A2 20000801
US 2000-727950	A2 20001201
US 1997-966076	A 19971107
WO 1998-US17657	W 19980826
US 2000-615340	A3 20000712
US 2000-228612P	P 20000828
US 2001-789350	B2 20010221
US 2001-819924	A 20010328
US 2001-828761	A 20010409
US 2001-839785	A 20010420
US 2001-841389	A 20010424
US 2001-897164	A3 20010702
WO 2001-US44352	W 20011127

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

IT 128470-16-6, Arbutamine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for in vivo drug delivery based on monitoring blood flow parameters)

RN 128470-16-6 HCAPLUS

CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 6 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:354101 HCAPLUS
DOCUMENT NUMBER: 136:355062
TITLE: Preparation of novel multi-binding phenolic compounds as β2-adrenergic receptor agonists
INVENTOR(S): Moran, Edmund J.; Griffin, John H.; Choi, Seok-ki
PATENT ASSIGNEE(S): Theravance, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 92 pp., Cont. of U.S. Ser. No. 323,943.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020055651	A1	20020509	US 2001-934982	20010821 <--
US 6683115	B2	20040127		
US 6541669	B1	20030401	US 1999-323943	19990602
CA 2318894	A1	19991216	CA 1999-2318894	19990604 <--
AU 9945435	A	19991230	AU 1999-45435	19990604 <--
EP 1003540	A1	20000531	EP 1999-928344	19990604 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002517457	T	20020618	JP 2000-553099	19990604 <--
CA 2318055	A1	19991216	CA 1999-2318055	19990607 <--
CA 2318286	A1	19991216	CA 1999-2318286	19990607 <--
CA 2319068	A1	19991216	CA 1999-2319068	19990607 <--
CA 2319159	A1	19991216	CA 1999-2319159	19990607 <--
CA 2319175	A1	19991216	CA 1999-2319175	19990607 <--
CA 2319496	A1	19991216	CA 1999-2319496	19990607 <--
CA 2319751	A1	19991216	CA 1999-2319751	19990607 <--
CA 2319756	A1	19991216	CA 1999-2319756	19990607 <--
CA 2321170	A1	19991216	CA 1999-2321170	19990607 <--
CA 2321273	A1	19991216	CA 1999-2321273	19990607 <--
AU 9944234	A	19991230	AU 1999-44234	19990607 <--
AU 9944265	A	19991230	AU 1999-44265	19990607 <--
AU 9945491	A	19991230	AU 1999-45491	19990607 <--
AU 9945520	A	19991230	AU 1999-45520	19990607 <--
AU 9946727	A	19991230	AU 1999-46727	19990607 <--
AU 9946751	A	19991230	AU 1999-46751	19990607 <--
AU 9946752	A	19991230	AU 1999-46752	19990607 <--

AU 9946754 A 19991230 AU 1999-46754 19990607 <--
EP 1019360 A1 20000719 EP 1999-930123 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1080080 A1 20010307 EP 1999-930158 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1083917 A1 20010321 EP 1999-927291 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1083893 A1 20010321 EP 1999-927331 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1083888 A1 20010321 EP 1999-928425 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085887 A2 20010328 EP 1999-928349 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085870 A2 20010328 EP 1999-930157 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1094826 A1 20010502 EP 1999-930156 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1100519 A1 20010523 EP 1999-930155 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1107753 A1 20010620 EP 1999-928457 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 2002517420 T 20020618 JP 2000-553004 19990607 <--
JP 2002517459 T 20020618 JP 2000-553102 19990607 <--
JP 2002517463 T 20020618 JP 2000-553110 19990607 <--
CA 2319497 A1 19991216 CA 1999-2319497 19990608 <--
CA 2319643 A1 19991216 CA 1999-2319643 19990608 <--
CA 2319651 A1 19991216 CA 1999-2319651 19990608 <--
CA 2320926 A1 19991216 CA 1999-2320926 19990608 <--
CA 2321120 A1 19991216 CA 1999-2321120 19990608 <--
CA 2321152 A1 19991216 CA 1999-2321152 19990608 <--
CA 2319650 A1 19991229 CA 1999-2319650 19990608 <--
AU 9943368 A 19991230 AU 1999-43368 19990608 <--
AU 9943376 A 19991230 AU 1999-43376 19990608 <--
AU 9946747 A 19991230 AU 1999-46747 19990608 <--
AU 9952039 A 19991230 AU 1999-52039 19990608 <--
AU 9946776 A 20000110 AU 1999-46776 19990608 <--
EP 1082289 A1 20010314 EP 1999-930185 19990608 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1083921 A1 20010321 EP 1999-955430 19990608 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085889 A2 20010328 EP 1999-928451 19990608 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085847 A2 20010328 EP 1999-928520 19990608 <--

	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085868		A1	20010328	EP 1999-930150	19990608 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1085894		A1	20010328	EP 1999-937155	19990608 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1102597		A1	20010530	EP 1999-955431	19990608 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002517442		T	20020618	JP 2000-553068	19990608 <--
US 6288055		B1	20010911	US 2000-499476	20000207 <--
ZA 2000003475		A	20011011	ZA 2000-3475	20000711 <--
ZA 2000004083		A	20011112	ZA 2000-4083	20000810 <--
ZA 2000004085		A	20011112	ZA 2000-4085	20000810 <--
ZA 2000004087		A	20011113	ZA 2000-4087	20000810 <--
ZA 2000004084		A	20011119	ZA 2000-4084	20000810 <--
ZA 2000004561		A	20011130	ZA 2000-4561	20000831 <--
ZA 2000004565		A	20011130	ZA 2000-4565	20000831 <--
US 20030087306		A1	20030508	US 2001-15534	20011213
US 20030087307		A1	20030508	US 2002-108945	20020328
US 6916961		B2	20050712		

PRIORITY APPLN. INFO.:	US 1998-88466P	P	19980608
	US 1998-92938P	P	19980715
	US 1999-323943	A1	19990602
	WO 1999-US11786	W	19990604
	US 1999-327044	B1	19990607
	WO 1999-US11803	W	19990607
	WO 1999-US11805	W	19990607
	WO 1999-US12669	W	19990607
	WO 1999-US12673	W	19990607
	WO 1999-US12727	W	19990607
	WO 1999-US12728	W	19990607
	WO 1999-US12730	W	19990607
	WO 1999-US12731	W	19990607
	WO 1999-US12778	W	19990607
	WO 1999-US12782	W	19990607
	US 1999-327904	B1	19990608
	WO 1999-US12626	W	19990608
	WO 1999-US12770	W	19990608
	WO 1999-US12876	W	19990608
	WO 1999-US12907	W	19990608
	WO 1999-US12989	W	19990608
	WO 1999-US12994	W	19990608
	WO 1999-US12995	W	19990608
	US 1999-457618	B1	19991208
	US 2000-493462	B1	20000128
	US 2000-637899	A1	20000814

OTHER SOURCE(S): MARPAT 136:355062
GI



I



II

AB Methods for preparing novel multibinding phenolic compds., LpXq [where L = a ligand capable of binding to a β2-adrenergic receptor; X = a linker; p = 2-10; q = 1-20], which serve as β2-adrenergic receptor agonists, are disclosed. Preferred ligands are of formula I [R1 = H, (un)substituted alkyl, or a bond linking ligand to linker; R2 = H, aralkyl, acyl, (un)substituted alkyl, cycloalkyl or a bond linking ligand to linker; W = bond, (un)substituted alkylene wherein one or more carbon atoms is optionally replaced by NR3, O, S, SO, SO2, CO, P-alkyl, PO2, OP(O)O or the alkylene optionally links the ligand to a linker with provisions; R3 = H, alkyl, acyl, or bond linking ligand to linker; X = aryl, heteroaryl, heterocyclyl and (un)substituted cycloalkyl wherein each X optionally links the ligand to the linker]. II was prepared from α,α-dihydroxy-4-hydroxy-3-methoxycarbonylacetophenone via condensation with trans-1,4-diaminocyclohexane with subsequent reduction of intermediate imine. In addition, combinatorial arrays of multimeric ligands and methods of assaying the multimeric ligands are embodied by the invention. As β2-adrenergic receptor agonists, the compds. are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis (no data). The title compds. are also useful in the treatment of nervous system injuries and premature labor. Formulations for capsules, tablets, dry power inhaler, suppositories and suspensions are described.

IT 321708-37-6P, 1,3-Benzenedimethanol, 4-hydroxy-α1-[[[4-[2-[[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]amino]methyl]- RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenolic β2-adrenergic receptor agonists)

RN 321708-37-6 HCAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy-α1-[[[4-[2-[[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]amino]methyl]- (CA INDEX NAME)



L10 ANSWER 7 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:185688 HCAPLUS
DOCUMENT NUMBER: 136:252567
TITLE: Methods for drug administration and distribution based on monitoring blood viscosity and other parameters for diagnostics and treatment
INVENTOR(S): Kensey, Kenneth
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 819,924.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20020032149	A1	20020314	US 2001-841389	20010424	<--
US 6019735	A	20000201	US 1997-919906	19970828	<--
CA 2301161	A1	19990304	CA 1998-2301161	19980826	<--
WO 9910724	A2	19990304	WO 1998-US17657	19980826	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
HU 2001000201	A2	20010528	HU 2001-201	19980826	<--
HU 2001000201	A3	20040329			
NZ 502905	A	20010831	NZ 1998-502905	19980826	<--
JP 2001514384	T	20010911	JP 2000-507994	19980826	<--
US 6322524	B1	20011127	US 1999-439795	19991112	<--
US 6322525	B1	20011127	US 2000-501856	20000210	<--
NO 2000000944	A	20000225	NO 2000-944	20000225	<--
MX 200002073	A	20010821	MX 2000-2073	20000228	<--
US 6428488	B1	20020806	US 2000-615340	20000712	
WO 2002009583	A2	20020207	WO 2001-US23696	20010730	<--
WO 2002009583	A3	20020425			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,					

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20020088953 A1 20020711 US 2001-33841 20011227 <--
US 6624435 B2 20030923
WO 2002079778 A2 20021010 WO 2002-US3984 20020207
WO 2002079778 A3 20030710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG
US 20020184941 A1 20021212 US 2002-156165 20020528
US 6571608 B2 20030603
PRIORITY APPLN. INFO.: US 1997-919906 A2 19970828
US 1999-439795 A2 19991112
US 2000-501856 A2 20000210
US 2000-628401 A2 20000801
US 2000-727950 A2 20001201
US 2001-819924 A2 20010328
US 1997-966076 A 19971107
WO 1998-US17657 W 19980826
US 2000-615340 A3 20000712
US 2000-228612P P 20000828
US 2001-789350 B2 20010221
US 2001-828761 A 20010409
US 2001-839785 A 20010420
US 2001-841389 A 20010424
US 2001-897164 A3 20010702

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being, i.e., a human, over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream. For example, when blood viscosity is a blood flow parameter monitored, an agent is selected from i.v. diluents, red blood cell deformability agents, antiurea agents, oral contraceptives, antidiabetic agents, antiarrhythmics, antihypertensives, antihyperlipidemics, antiplatelet agents, appetite suppressants, antiobesity agents, blood modifiers, smoking deterrent agents, and nutritional supplements.

IT 128470-16-6, Arbutamine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(apparatus and methods for monitoring blood viscosity and other parameters in drug delivery for diagnostics and treatment)

RN 128470-16-6 HCAPLUS

CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 8 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:157723 HCAPLUS

DOCUMENT NUMBER: 136:216523

TITLE: Preparation of phenylethanol(mono/di)amines and phenylalkylethanol(mono/di)amines as sodium channel blockers

INVENTOR(S): Fuchs, Klaus; Stransky, Werner; Grauert, Matthias; Carter, Adrian; Gaida, Wolfram; Weiser, Thomas; Ensinger, Helmut

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016308	A1	20020228	WO 2001-EP9036	20010804 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10040901	A1	20020314	DE 2000-10040901	20000818 <--
US 20020042410	A1	20020411	US 2001-912163	20010724 <--
US 6770636	B2	20040803		
AU 2001091737	A	20020304	AU 2001-91737	2001080 4 <--
CA 2417361	A1	20030124	CA 2001-2417361	20010804
EP 1311471	A1	20030521	EP 2001-971870	20010804

EP 1311471	B1	20060412			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004506710	T	20040304	JP 2002-521184		20010804
AT 323066	T	20060415	AT 2001-971870		20010804
ES 2261471	T3	20061116	ES 2001-971870		20010804
MX 2003PA01454	A	20040504	MX 2003-PA1454		20030217
PRIORITY APPLN. INFO.:			DE 2000-10040901	A	20000818
			US 2000-228675P	P	20000829
			WO 2001-EP9036	W	20010804

OTHER SOURCE(S): MARPAT 136:216523

GI



I



II

AB Title compds. [I; R1 = OH, CF3, NO2, CN, halo, C1-8 alkyl, halo, C1-8 alkoxy; R2, R3, R4 independently = halo, C1-8 alkyl, OH, NO2, CN, C1-8 alkoxy, CF3; R5, R6 independently = C1-8 alkyl, C2-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, NH2, OH, O, COOH, CONH2; A = C1-5 alkylene, C2-4 alkenylene, C3-4 alkylene; X = NH, N(CHO), halo, O, etc.] are prepared The invention further relates to a method for producing said compds. and to their composition in use as medicaments. Title compds. I are used as blockers of the voltage-dependent sodium channel and can be used for diseases that are associated with a functional disorder caused by hyperexcitability. Thus, the title compound II was prepare from trifluoroacetic anhydride, 2,6-dimethylbenzaldehyde, which was prepared from 2-bromo-3-dimethylbenzene, and 2-(3-bromopropyl)-1,3-difluorobenzene, which was prepared from di-Et malonate and 2,6-difluorobenzyl bromide.

IT 401939-54-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylethanolamines and phenylalkylethanolamines as sodium channel blockers)
RN 401939-54-6 HCAPLUS
CN Benzenepropanaminium, N-[2-[3-(2,6-difluorophenyl)propoxy]-2-(2,6-dimethylphenyl)ethyl]-N,N-dimethyl-, iodide (1:1) (CA INDEX NAME)



● I-

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:72073 HCAPLUS
DOCUMENT NUMBER: 136:134753
TITLE: Preparation of arylaminothizolidines and analogs as β3 adrenergic receptor agonists
INVENTOR(S): Malamas, Michael Sotirios; Largis, Elwood Eugene; Gunawan, Iwan; Li, Zenan
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006258	A1	20020124	WO 2001-US22408	20010716 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 20020032222	A1	20020314	US 2001-904161	20010712 <--
US 6465501	B2	20021015		
US 20030055079	A1	20030320	US 2002-227225	20020823
US 6569873	B2	20030527		

PRIORITY APPLN. INFO.: US 2000-218706P P 20000717
US 2001-904161 A3 20010712

OTHER SOURCE(S): MARPAT 136:134753

GI



AB R1Z1CH(OH)CH2NHCHR4Z2Z3NR5ZR6 [I; R1 = (un)substituted Ph, -pyridyl, etc.; R4 = H or alkyl; R5 = H, alkyl, alkoxycarbonyl, aryl, etc.; R6 = H, alkyl, aryl(alkyl); Z = e.g., 2,4-dioxothiazolidine-5,3-diyl; Z1 = bond, OCH2, SCH2; Z2 = bond, C1-6 alkyl (sic), C1-6 alkoxy (sic); Z3 = phenylene, naphthylene, benzofurylene, benzothienylene] were prepared Thus, (S)-oxiranylmethyl 3-nitrobenzenesulfonate was etherified by 4-(PhO)C6H4OH and the product aminated by 4-(H2N)C6H4CH2CH2NH2 to give, after N-protection, (S)-4-(PhO)C6H4OCH2CH(OH)CH2N(CO2CMe3)CH2CH2C6H4(NH2)-4 which was N-alkylated by 5-bromothiazolidine-2,4-dione to give, after deprotection, title compound II. Data for biol. activity of I were given.

IT 321575-09-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylaminothizolidines and analogs as β3 adrenergic receptor agonists)

RN 321575-09-1 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:72065 HCAPLUS
DOCUMENT NUMBER: 136:118440
TITLE: Preparation of substituted arylsulfides, arylsulfoxides and arylsulfones for use as β3 adrenergic receptor agonists
INVENTOR(S): Quagliato, Dominick Anthony; Andrae, Patrick Michael
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006250	A1	20020124	WO 2001-US22348	20010716 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020040023	A1	20020404	US 2001-903802	20010712 <--
US 6458817	B2	20021001		
PRIORITY APPLN. INFO.:			US 2000-218763P	P 20000717
OTHER SOURCE(S):	MARPAT 136:118440			

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. I (R1 = H, C1-6 alkyl or alkoxy, halogen, F3C, F3CO, OH, NO2, NH2, CN, CO2H, alkoxy- or aminocarbonyl, NR5SO2R5, etc.; R2 = H, C1-6 alkyl; R3 = H, C1-6 alkyl or alkoxy, halogen; R4 = 5-6 membered heterocycle with 1-4 heteroatoms of O, S, N (un)substituted with R6 or R6 (un)substituted Ph, phenylalkyl or C1-6 alkyl; R5 = H, Ph, C1-6 alkyl; R6 = C1-6 alkyl, halogen, F3C(O), OH, NH2, CN, CO2R5, etc.; A = 5-6 membered heterocycle with 1-4 heteroatoms of O, S, N or Ph ring; B = Ph or Ph fused heterocycle; Y = C1-6 alkyl; Z = bond, OCH2; m = 1-2; n = 0-2) or a pharmaceutically acceptable salt thereof were prepared and are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes. Thus 3-chloromethyl-5-(4-methoxyphenyl)-1,2,4-oxadiazole reacted with a BOC

protected amino xanthate yielding 4-({[5-(4-methoxyphenyl)-1,2,4-oxadiazole-3-yl]methyl}sulfonyl)phenethylamine which when reacted with II afforded III. The β3 adrenergic receptor and maximal response of III for EC50(β3, μM) was 0.068 and for IA(β3) was 0.95 resp., demonstrating that the compds. have activity at the β3 adrenergic receptor.

IT 391672-07-4P
RL: FFD (Food or feed use); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); USES (Uses); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted arylsulfides, -sulfoxides and -sulfones for use as β3 adrenergic receptor agonists)

RN 391672-07-4 HCAPLUS

CN Methanesulfonamide, N-[5-[(1R)-2-[[2-[4-[[[5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methyl]sulfonyl]phenyl]ethyl]amino]-1-[(triethylsilyl)oxy]ethyl]-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:72044 HCAPLUS
DOCUMENT NUMBER: 136:134675
TITLE: Preparation of heterocyclic amino alcohol beta-3 adrenergic receptor agonists

INVENTOR(S): Ashwell, Mark Anthony; Solvibile, William Ronald; Quagliato, Dominick Anthony; Molinari, Albert John
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006229	A2	20020124	WO 2001-US22327	20010716 <--
WO 2002006229	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020028832	A1	20020307	US 2001-903841	20010712 <--
US 6451814	B2	20020917		
US 20030018045	A1	20030123	US 2002-189312	20020702
US 6605618	B2	20030812		

PRIORITY APPLN. INFO.: US 2000-218628P P 20000717
US 2001-903841 A1 20010712

AB This invention provides A-U-CH(OH)CH2NHCH2CH2VC6H4WZ-p (1; Z = (1-Y-X-substituted piperidin-4-yl)) or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes. β3-Adrenergic receptor EC50 and maximal response (IA; % activity compound/% activity isoproterenol) values are reported for .apprx.100 example compds., e.g. 0.032 μM and 1.04 for 4-[4-[2-[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propylamino]ethyl]phenylamino]piperidine-1-carboxylic acid 2,6-difluorobenzylamide. In 1, A is (a) a 5-6 membered heterocyclic ring having 1-4 heteroatoms selected from O, N, and S, substituted with (R1)m; (b) a Ph ring substituted with (R1)m; (c) a naphthyl ring substituted with (R1)m; or (d) a Ph fused heterocycle selected from (R1)m-substituted 1,3-dihydro-2-oxo-2H-benzimidazol-4-yl, 1,3-benzodioxol-5-yl, 1,2,3,4-tetrahydro-2-oxoquinolin-5-yl, 1,2,3,4-tetrahydro-1-naphthylideneamino. U is -OCH2- or a bond; V is O or a bond; W is O, S(O)a, NR2, NC(O)R2; X = SO2, C(O), -(CH2)b, a bond, Ar; Y is -NR3R4, Het, Ar, alkyl of 1-8 C atoms, O(CH2)dR5. R1 is alkyl of 1-8 C atoms, -OR6, halogen, cyano, cycloalkyl of 3-8 C atoms, trifluoromethyl, CO2R6, -NR6R7, -C(O)NR6R7, -NHC(O)R6, -NR6C(O)NR8R8, -NHSO2R8, -S(O)aR6, -NO2, -O(CH2)eCO2R7, -OC(O)NR6R7, -O(CH2)fOR6, or a 5-6 membered heterocyclic ring containing 1 to 4 heteroatoms selected from O, S, and N. R2 is H, alkyl of 1-8 C atoms, or arylalkyl having 1-8 C atoms in the alkyl moiety; R3 and R4 are each, independently, H, alkyl of 1-8 C atoms,

cycloalkyl of 3-8 C atoms, arylalkyl having 1-8 C atoms in the alkyl group, -(CH2)gR9, -(CH2)hCOR9, -(CH2)jCR10R11(CH2)jR9, or -(CH2)kCONR12R13; or R3 and R4 may be taken together together with the N to which they are attached to form a 3-7 membered saturated heterocycle, which may optionally contain 1-2 addnl. heteroatoms selected from O and S, and said heterocycle may optionally be substituted with R14. R5 is H; alkyl of 1-8 C atoms optionally substituted by 1-3 substituents selected from hydroxy, halogen and aryl; cycloalkyl of 1-8 C atoms; Ar or Het; R6, R7, and R8 are each, independently, H, or alkyl of 1-8 C atoms, or aryl of 6-10 C atoms, cycloalkyl of 3-8 C atoms, or arylalkyl having 1-8 C atoms in the alkyl moiety; R9 is H; alkyl optionally substituted with 1-3 substituents selected from hydroxy, halogen, and aryl; cycloalkyl of 3-8 C atoms; Ar, or Het; R10 and R11 are each, independently, H, alkyl, or aryl optionally substituted with alkyl of 1-8 C atoms or halogen; or R10 and R11 are taken together to form a spiro fused cycloalkyl ring of 3-8 C atoms. R12 and R13 are each, independently, H, alkyl of 1-8 C atoms, aryl optionally substituted with alkyl of 1-8 C atoms or halogen; or R12 and R13 are taken together with the N to which they are attached to form a 3-7 membered saturated heterocycle, which may optionally contain 1-2 addnl. heteroatoms selected from O and S, and said heterocycle may optionally be substituted with R14; R14 is CO2R15 or aryl optionally substituted with a 1-3 substituents selected from -OR15 and cycloalkyloxy of 3-8 C atoms; R15 is alkyl of 1-8 C atoms or arylalkyl having 1-8 C atoms in the alkyl moiety. Ar is an aromatic ring system containing 1-2 carbocyclic aromatic rings having 6-10 C atoms optionally mono, di, or trisubstituted with R16; Het is (a) a 5-6 membered heterocyclic ring having 1-4 heteroatoms selected from O, S, and N which may be optionally mono- or disubstituted with R16; or (b) a heterocyclic ring system optionally mono- or disubstituted by R16 containing a 5-6 membered heterocyclic ring fused to one or two carbocyclic or heterocyclic rings such that the heterocyclic ring system contains 1-4 heteroatoms selected from O, S, and N; R16 is aryl, halogen, alkyl of 1-8 C atoms, -OR17, cycloalkyl of 3-8 C atoms, trifluoromethyl, cyano, -CO2R17, -CONR17R18, -SO2NR17R18, -NR17OR18, -NR19CONR1 7R18, -NR17R18, -NR17COR18, -NO2, -O(CH2)pCO2R17, -OCONR17R18, -S(O)nR17, -O(CH2)qOR17, or a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from O, S and N. R17, R18, and R19 are each, independently, H, alkyl of 1-8 C atoms, arylalkyl having 1-8 C atoms in the alkyl moiety, or aryl optionally mono, di, or trisubstituted with halogen, cyano, nitro, hydroxy, alkyl of 1-8 C atoms, or alkoxy of 1-8 C atoms; or when R17 and R18 are contained on a common N, R17 and R18 may be taken together with the N to which they are attached to form a 3-7 membered saturated heterocycle, which may optionally contain 1-2 addnl. heteroatoms selected from O and S. A = 0-2; b = 1-6; d = 0-3; e = 1-6; f = 1-6; g = 0-6; h = 0-6; j = 0-6; k = 0-6; m = 0-2; p = 1-6; q = 1-6. Methods of preparation are claimed, comprising (a) reacting AOCH2-substituted oxirane or a protected form thereof in which a reactive substituent group is protected, with H2NCH2CH2VC6H4WZ-p or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 (U = -OCH2-). (b) reacting A-substituted oxirane or a protected form thereof in which any reactive substituent group is protected, with H2NCH2CH2VC6H4WZ-p or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 wherein U represents a bond;. (c) reacting ACH(OPr)CH2I, wherein Pr is a protecting group, with H2NCH2CH2VC6H4WZ-p or a protected form thereof in which a reactive substituent group is

protected; and if required removing any protecting group to give 1 wherein U = -OCH2-. (d) reacting ACH(OH)CH2NH2 or a protected form thereof in which any reactive substituent group is protected, with HO2CCH2VC6H4WZ-p or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 wherein U = -OCH2-. (e) removing any protecting group from 1 in which at least one substituent carries a protecting group to give 1; or (f) converting a basic compound 1 to a salt thereof by reaction with a pharmaceutically acceptable acid; or (g) converting 1 having one or more reactive substituent groups to a different 1; or (h) isolating an isomer of 1 from a mixture thereof. More than 100 example prepns. are included.

IT 392630-65-8P, 1-[4-[4-[2-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylamino]ethyl]phenylamino]piperidine-1-carbonyl]piperidine-4-carboxylic acid ethyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); USES (Uses); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of heterocyclic amino alc. beta-3 adrenergic receptor agonists)

RN 392630-65-8 HCAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[4-[[4-[2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]ethyl]phenyl]amino]-1-piperidinyl]carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

OEt

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:16649 HCAPLUS
DOCUMENT NUMBER: 137:105812
TITLE: Assessment of adenosine, arbutamine and dobutamine as pharmacological stress agents during 99mTc-tetrofosmin SPECT imaging: a randomized study
AUTHOR(S): Wright, D. J.; Williams, S. G.; Lindsay, H. S. J.; Sheard, K. L.; Thorley, P. J.; Sivananthan, U. M.
CORPORATE SOURCE: The Cardiothoracic Centre, Liverpool, L14 3PE, UK
SOURCE: Nuclear Medicine Communications (2001), 22(12), 1305-1311
CODEN: NMCODC; ISSN: 0143-3636
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We evaluated the use of adenosine, dobutamine and arbutamine with 99mTc-tetrofosmin myocardial perfusion imaging. Forty patients under investigation for suspected coronary artery disease were recruited. Each had a resting scan and two sep. stress scans on different days, in a randomized cross-over study. Resultant images were blindly reported in 13 segments per scan as normal, reversible or fixed defects. A score was given (0-3) for segmental defect severity. Haemodynamic responses were as expected for each agent. Subjective side effect scores did not differ overall between agents. Adenosine caused a significantly higher incidence of abnormal taste (54%) than dobutamine and arbutamine (both 23%) and a lower incidence of palpitations (25% vs 69% and 54%, resp.), all P<0.05. Arbutamine caused significantly more chest pain than adenosine (77% vs 46%) though less flushing (35% vs 68%), both P<0.05. Comparison of the results obtained showed highly significant levels of segmental agreement for visual and semi-quant. anal. between adenosine and arbutamine, κ value and correlation coefficient of 0.78 and 0.86, resp., dobutamine and adenosine 0.69 and 0.78, and arbutamine and dobutamine 0.75 and 0.78, all P<0.0001. Adenosine, arbutamine and dobutamine differ in their hemodynamic response and side effect profile but provide highly comparable results during 99mTc SPECT imaging.
IT 128470-16-6, Arbutamine
RL: ADV (Adverse effect, including toxicity); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(assessment of adenosine, arbutamine and dobutamine as pharmacol. stress agents during 99mTc-tetrofosmin SPECT imaging)
RN 128470-16-6 HCAPLUS
CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:10442 HCAPLUS
DOCUMENT NUMBER: 136:85762
TITLE: New aryl-, quinolyl-, and other heterocyclyl-containing amino alcohol derivatives useful as β3 adrenergic receptor agonists
INVENTOR(S): Kayakiri, Hiroshi; Sakurai, Minoru; Washizuka, Kenichi; Hamashima, Hitoshi; Tomishima, Yasuyo; Fujii, Naoaki; Taniguchi, Kiyoshi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000622	A2	20020103	WO 2001-JP5425	20010625 <--
WO 2002000622	A3	20020829		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: AU 2000-8413 A 20000627
OTHER SOURCE(S): MARPAT 136:85762
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. I [wherein: X1 = bond or OCH2; X2 = (CH2)1-2; X3 = bond, O, or NH; R1 = (un)substituted Ph, indolyl, or carbazolyl [substituents = 1 or 2 of OH, halo, NO2, amino, formyl, (lower)alkylsulfonylamino, aryl(lower)alkoxy, and hydroxy(lower)alkyl]; R2 = H or aryl(lower)alkyl; R3 = H or hydroxy(lower)alkyl; R4 = (un)substituted aryl, 4-quinolyl, phthalazinyl, quinazolinyl, cinnolinyl, or naphthyridinyl; with provisos], or their pharmaceutically acceptable salts. The compds. are β3 adrenergic receptor agonists, and therefore have gut sympathomimetic, antiulcer, anti-pancreatitis, lipolytic, and smooth muscle relaxant activities. In particular, I and salts are useful for the prophylactic and/or the therapeutic treatment of pollakiuria or urinary incontinence. Sixty precursor prepns. and 63 invention examples, including well over 200 invention compds., are provided. For example, the structure of claimed compound II is typical.

Another invention compound, phthalazine derivative III, was prepared from 4-((2S)-2-amino-3-hydroxypropyl)phenol HCl, benzaldehyde, (2S)-3-phenoxy-1,2-epoxypropane, and 1-chlorophthalazine, in 4 steps. III at 0.32 mg/kg (intraduodenal) in beagle dogs gave 35.9% inhibition of carbachol-induced increase in intravesical pressure.

IT 386208-92-0P, N-[[4-[4-[2-[N-Benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenoxy]-7-quinolyl]carbonyl]methanesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aryl- and quinolyl-containing amino alcs. and analogs as β3-adrenergic receptor agonists)

RN 386208-92-0 HCAPLUS

CN 7-Quinolinecarboxamide, 4-[4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl](phenylmethyl)amino]ethyl]phenoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2001:904118 HCAPLUS
DOCUMENT NUMBER:	136:37625
TITLE:	Preparation of pyridazinones as β2-adrenoreceptor agonists and PDE4 inhibitors
INVENTOR(S):	Hatzelmann, Armin; Bundschuh, Daniela; Eltze, Manfrid; Van der Laan, Yvonne; Timmermann, Hendrik; Christiaans, Johannes; Brundel, Paulus; Sterk, Geert
PATENT ASSIGNEE(S):	Byk Gulden Lomberg Chemische Fabrik G.m.b.H., Germany; Byk Nederland B.V.
SOURCE:	PCT Int. Appl., 79 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

10521294

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094319	A1	20011213	WO 2001-EP6230	20010601 <--
W: AE, AL, AU, BA, BG, BR, CA, CN, CO, CU, CZ, EC, EE, GE, HR, HU, ID, IL, IN, IS, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2411351	A1	20011213	CA 2001-2411351	20010601 <--
EP 1296956	A1	20030402	EP 2001-936419	20010601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011440	A	20030603	BR 2001-11440	20010601
JP 2003535850	T	20031202	JP 2002-501869	20010601
HU 2003001240	A2	20031229	HU 2003-1240	20010601
HU 2003001240	A3	20040329		
NZ 522882	A	20040730	NZ 2001-522882	20010601
AU 2001262332	B2	20060525	AU 2001-262332	20010601
IN 2002MN01591	A	20050318	IN 2002-MN1591	20021111
ZA 2002009598	A	20030729	ZA 2002-9598	20021126
NO 2002005811	A	20030204	NO 2002-5811	20021203
MX 2002PA12042	A	20040819	MX 2002-PA12042	20021205
US 20030195215	A1	20031016	US 2003-296411	20030402
US 6933296	B2	20050823		

PRIORITY APPLN. INFO.:		EP 2000-111795	A 20000605
		WO 2001-EP6230	W 20010601

OTHER SOURCE(S): MARPAT 136:37625

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; Ar1 = substituted Ph, dihydrobenzofuranyl; R6, R7 = H, alkyl; or R6 and R7 together and with inclusion of the two carbon atoms, to which they are bonded, form II-V; A = CmH2mYXCnH2n, YXCmH2mZCnH2n; X = a bond, O, S, etc.; Y = a bond, phenylene, cycloalkylene, etc.; Z = O, S, SO2, etc.; m = 0-4; n = 1-4; R8 = H, alkyl; Ar2 = 8-hydroxy-1H-quinolin-2-on-5-yl, substituted Ph], useful as novel effective bronchial therapeutics, were prepared The general procedures for preparation of compds. I such as (cis)-VI.fumarate were described. Biol. data for compds. I were given.

IT 380226-27-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridazinones as β2-adrenoreceptor agonists and PDE4 inhibitors)

RN 380226-27-7 HCAPLUS

CN 1(2H)-Phthalazinone, 2-[4-[2-[[2-(4-amino-3,5-dichlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-4-(3,4-dimethoxyphenyl)-4a,5,8,8a-tetrahydro-, (4aR,8aS)-rel-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

Updated Search

CM 1

CRN 380226-26-6
CMF C32 H34 Cl2 N4 O4

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 15 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:872220 HCAPLUS
DOCUMENT NUMBER: 136:303557
TITLE: 4-Aminopiperidine ureas as potent selective agonists of the human β3-Adrenergic receptor
AUTHOR(S): Ashwell, Mark A.; Solvibile, William R.; Han, Stella; Largis, Elwood; Mulvey, Ruth; Tillet, Jeffrey
CORPORATE SOURCE: Chemical Sciences, Wyeth-Ayerst Research, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(24), 3123-3127
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal

LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:303557
GI



I

AB The preparation and structure-activity relationships (SARs) of potent agonists of the human β3-adrenergic receptor (AR) derived from a 4-aminopiperidine scaffold are described. Examples combine human β3-AR potency with selectivity over human β1-AR and/or human β2-AR agonism. I (R1 = H, alkyl, benzyl derivative, etc; R2 = H or ethyl; Ar = phenoxy or other aryl derivative) was identified as a potent (EC50=1 nM) and selective (greater than 400-fold over β1- with no β2-AR agonism) full β3-AR agonist with in vivo activity in a transgenic mouse model of thermogenesis.

IT 392634-99-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(4-Aminopiperidine ureas as potent selective agonists of human β3-Adrenergic receptor in relation to thermogenesis and structure)

RN 392634-99-0 HCAPLUS

CN 1-Piperidinecarboxamide, N-[(2,5-difluorophenyl)methyl]-4-[[4-[2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]amino]ethyl]phenyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:798200 HCAPLUS
DOCUMENT NUMBER: 135:344482
TITLE: Preparation of substituted 4-(heteroarylmethyl)benzonitriles as farnesyltransferase inhibitors
INVENTOR(S): Wang, Wei-Bo; Curtin, Michael L.; Fakhoury, Stephen A.; Gwaltney, Stephen L., II; Hasvold, Lisa A.; Hutchins, Charles W.; Li, Qui; Lin, Nan-Horng; Jennings Nelson, Lissa Taka; O'Connor, Stephen J.; Sham, Hing L.; Sullivan, Gerald M.; Wang, Gary T.; Wang, Xilu
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 305 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081316	A2	20011101	WO 2001-US13678	20010425 <--
WO 2001081316	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2407093	A1	20011101	CA 2001-2407093	20010425 <--
EP 1276726	A2	20030122	EP 2001-932712	20010425
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509064	T	20040325	JP 2001-578410	20010425
MX 2002PA10608	A	20030514	MX 2002-PA10608	20021025

PRIORITY APPLN. INFO.:

US 2000-563256	A	20000427
US 2001-822205	A	20010402
WO 2001-US13678	W	20010425

OTHER SOURCE(S): MARPAT 135:344482
GI



AB The title compds. [I; A1 = (un)substituted alkylene, etc.; R1 = halo, cycloalkyl, aryl, heteroaryl; R2 = heteroaryl selected from imidazolyl, pyrazolyl, pyrrolyl, etc.] and their pharmaceutically acceptable salts which farnesyltransferase, were prepared E.g., 3-step synthesis of the benzonitrile II.HCl which 88% inhibition of farnesyltransferase at 10-6 M, was given.

IT 371764-67-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 4-(heteroarylmethyl)benzonitriles as farnesyltransferase inhibitors)

RN 371764-67-9 HCAPLUS

CN Benzonitrile, 4-[[(2-hydroxy-2-phenylethyl)(2-phenylethyl)amino](1-methyl-1H-imidazol-5-yl)methyl]-2-(1-naphthalenyl)- (CA INDEX NAME)



L10 ANSWER 17 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:716519 HCAPLUS
DOCUMENT NUMBER: 135:242138
TITLE: Preparation of amide derivatives as β3 adrenergic receptor agonists
INVENTOR(S): Ashton, Wallace T.; Mathvink, Robert; Naylor,

Elizabeth M.; Parmee, Emma R.; Weber, Ann E.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: Brit. UK Pat. Appl., 45 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2356197	A	20010516	GB 2000-24805	20001010 <--
US 6291491	B1	20010918	US 2000-689169	20001012 <--

PRIORITY APPLN. INFO.: US 1999-158871P P 19991012
GI



AB Pyridine amide derivs. I (m = 0-5; n = 0-5; A = benzene, 5- or 6-membered heterocyclic ring with 1-4 atoms = O, S, N or benzene fused to a heterocyclic ring; X = C1-C3 alkylene, O, amino, bond; Z = Ph, naphthyl, 5- or 6-membered heterocyclic ring, carbocyclic fused benzene, benzene fused to a heterocyclic ring; R, R1 = (un)-substituted C1-10-alkyl, C3-8-cycloalkyl, oxo, halo, CN, etc.; R2 = R3 H, C1-10-alkyl) were prepared for use as β3 adrenergic receptor agonists (no data). Thus II was prepared in 47% yield in a multistep synthesis for use in the treatment of diabetes, obesity, lowering of triglyceride and cholesterol levels or for raising high d. lipoprotein levels or to decrease gut motility and to reduce airway neurogenic inflammation.

IT 359794-38-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amide derivs. as β3 adrenergic receptor agonists)

RN 359794-38-0 HCAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[(2R)-2-(3-cyanophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 18 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:435027 HCAPLUS
DOCUMENT NUMBER: 135:45979
TITLE: Preparation of 4-(arylhydroxyethylaminoethyl)phenylaminohydroxyethylbenzenes and related compounds as β2 adrenergic receptor agonists and partial agonists.
INVENTOR(S): Moran, Edmund J.; Griffin, John H.; Choi, Seok-ki
PATENT ASSIGNEE(S): Advanced Medicine, Inc., USA
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042193	A1	20010614	WO 2000-US33057	20001206 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6576793	B1	20030610	US 2000-637899	20000814
ZA 2000005850	A	20020517	ZA 2000-5850	20001019 <--
CA 2391293	A1	20010614	CA 2000-2391293	20001206 <--
BR 2000015962	A	20020730	BR 2000-15962	20001206 <--
EP 1235787	A1	20020904	EP 2000-986271	20001206
EP 1235787	B1	20031029		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
HU 2002003638	A2	20030228	HU 2002-3638	20001206
HU 2002003638	A3	20030428		
JP 2003516381	T	20030513	JP 2001-543495	20001206
AT 253039	T	20031115	AT 2000-986271	20001206
PT 1235787	T	20040331	PT 2000-986271	20001206
ES 2208453	T3	20040616	ES 2000-986271	20001206
AU 781466	B2	20050526	AU 2001-22546	20001206
US 20030087307	A1	20030508	US 2002-108945	20020328
US 6916961	B2	20050712		

ZA 2002003450	A	20030513	ZA 2002-3450		20020430
IN 2002CN00829	A	20070302	IN 2002-CN829		20020604
NO 2002002655	A	20020605	NO 2002-2655		20020605 <--
MX 2002PA05599	A	20020918	MX 2002-PA5599		20020606
HK 1048803	A1	20040130	HK 2003-101047		20030213
US 20050261338	A1	20051124	US 2005-49447		20050202
US 7217738	B2	20070515			
KR 2007039968	A	20070413	KR 2007-704447		20070223
US 20070179179	A1	20070802	US 2007-784148		20070405
US 7427639	B2	20080923			
US 20080269344	A1	20081030	US 2008-145658		20080625
PRIORITY APPLN. INFO.:			US 1999-457618	A	19991208
			US 2000-637899	A1	20000814
			US 1999-323943	A2	19990602
			WO 2000-US33057	W	20001206
			US 2002-108945	A1	20020328
			KR 2002-707322	A3	20020607
			US 2005-49447	A1	20050202
			US 2007-784148	A1	20070405

AB LpXq [p= 2-10; q = 1-20; X = linker, L = ligand; 1 ligand = Ar1CH(OH)CHR1NR2WAr2, the other = QAr3; Ar1, Ar2 = aryl, heteroaryl, heterocyclyl, (substituted) cycloalkyl; R1 = H, (substituted) alkyl, bond to linker; R2 = H, aralkyl, acyl, (substituted) alkyl, cycloalkyl, bond to linker; W = bond, (substituted) (heteroatom-interrupted) alkylene; Ar3 = aryl, heteroaryl, (substituted) cycloalkyl, heterocyclyl; Q = bond, (substituted) (heteroatom-interrupted) alkylene; with provisos], were prepared for treatment of respiratory diseases (no data). Thus, α,α-hydroxy-4-hydroxy-3-methoxycarbonylacetophenone (preparation given) was stirred with trans-1,4-diaminocyclohexane in THF for 3 h at room temperature followed by addition of BH3/Me2S in hexane and stirring for 4 h to give trans-1,4-bis[N-[2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethyl]amino]cyclohexane.

IT 321708-37-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylhydroxyethylaminoethylphenylaminohydroxyethylbenzenes and related compds. as β2 adrenergic receptor agonists and partial agonists)

RN 321708-37-6 HCAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy-α1-[[[4-[2-[[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]amino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:341599 HCAPLUS
DOCUMENT NUMBER: 135:352579
TITLE: Denopamine, a β1-adrenergic agonist, increases alveolar fluid clearance in ex vivo rat and guinea pig lungs
AUTHOR(S): Sakuma, Tsutomu; Tuchihara, Chiharu; Ishigaki, Masanobu; Osanai, Kazuhiro; Nambu, Yoshihiro; Toga, Hirohisa; Takahashi, Keiji; Ohya, Nobuo; Kurihara, Takayuki; Matthay, Michael A.
CORPORATE SOURCE: Department of Pulmonary Medicine, Kanazawa Medical University, Ishikawa, 920-0293, Japan
SOURCE: Journal of Applied Physiology (2001), 90(1), 10-16
CODEN: JAPHEV; ISSN: 8750-7587
PUBLISHER: American Physiological Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effect of denopamine, a selective β1-adrenergic agonist, on alveolar fluid clearance was determined in both ex vivo rat and guinea pig lungs. Alveolar fluid clearance was measured by the progressive increase in the concentration of Evans blue-labeled albumin over 1 h at 37°C. Denopamine (10-6 to 10-3 M) increased alveolar fluid clearance in a dose-dependent manner in ex vivo rat lungs. Denopamine also stimulated alveolar fluid clearance in guinea pig lungs. Atenolol, a selective β1-adrenergic antagonist, and amiloride, a sodium channel inhibitor, inhibited denopamine-stimulated alveolar fluid clearance. The potency of denopamine was similar to that of similar doses of isoproterenol or terbutaline. Short-term hypoxia (100% nitrogen for 1-2 h) did not alter the stimulatory effect of denopamine. Denopamine (10-4, 10-3 M) increased intracellular adenosine 3',5'-cyclic monophosphate levels in cultured rat alveolar type II cells. In summary, denopamine, a selective β1-adrenergic agonist, stimulates alveolar fluid clearance in both ex vivo rat and guinea pig lungs.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(denopamine, a β1-adrenergic agonist, increases alveolar fluid clearance in ex vivo rat and guinea pig lungs)
RN 71771-90-9 HCAPLUS
CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 20 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:290240 HCAPLUS
DOCUMENT NUMBER: 134:290411
TITLE: Method for determining viability of a myocardial segment
INVENTOR(S): Sawada, Stephen; St. Cyr, John; Johnson, Clarence A.
PATENT ASSIGNEE(S): Bioenergy Inc., USA
SOURCE: Brit. UK Pat. Appl., 18 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2351906	A	20010117	GB 2000-23105	20000921 <--
GB 2351906	B	20010718		
CA 2383600	A1	20010329	CA 2000-2383600	20000922 <--
CA 2383600	C	20080729		
WO 2001021218	A2	20010329	WO 2000-US26034	20000922 <--
WO 2001021218	A3	20020103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1214100	A2	20020619	EP 2000-963718	20000922 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509477	T	20030311	JP 2001-524641	20000922
AU 781731	B2	20050609	AU 2001-38854	20000922
MX 2002PA03151	A	20030820	MX 2002-PA3151	20020325

PRIORITY APPLN. INFO.: US 1999-405462 A 19990924
WO 2000-US26034 W 20000922

AB A method of determining the viability of a hibernating or stunned myocardial segment comprises the administration of ribose, a vasodilator, and an inotropic agent. The preferred agent is dobutamine, which has both

vasodilator and inotropic effects. The segments may be identified by myocardial imaging by any known means, e.g. echocardiog., thallium-201 tracing, or positron emission tomog. Ribose is preferably given 1 min. to 3 h prior to administration of the vasodilator and inotropic agents.

IT 128470-16-6, Arbutamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(myocardial segment viability determination using ribose, vasodilator, inotropic agent, and imaging method)

RN 128470-16-6 HCAPLUS

CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 21 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:150963 HCAPLUS

DOCUMENT NUMBER: 134:305158

TITLE: Beta1-adrenergic agonist is a potent stimulator of alveolar fluid clearance in hyperoxic rat lungs

AUTHOR(S): Sakuma, Tsutomu; Hida, Mieko; Nambu, Yoshihiro; Osanai, Kazuhiro; Toga, Hirohisa; Takahashi, Keiji; Ohya, Nobuo; Inoue, Masao; Watanabe, Yoh

CORPORATE SOURCE: Department of Thoracic Surgery, Division of Core Facility, Medical Research Institute, Kanazawa Medical University, Ishikawa, 920-0293, Japan

SOURCE: Japanese Journal of Pharmacology (2001), 85(2), 161-166
CODEN: JJPAAZ; ISSN: 0021-5198

PUBLISHER: Japanese Pharmacological Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Because it was still uncertain whether a stimulation of β1-adrenoceptors accelerated alveolar fluid clearance in hyperoxic lung injury, the effect of denopamine, a selective β1-adrenergic agonist, on alveolar fluid clearance was determined in rats exposed to 93% oxygen for 48 and 56 h. Alveolar fluid clearance was measured by the progressive increase in the concentration of Evans blue labeled albumin instilled
into the alveolar spaces over 1 h at 37 in isolated rat lungs. The principal results were as follows: (1) Although lung water volume increased in rats exposed to hyperoxia for 48 and 56 h, basal alveolar fluid

clearance did not change for up to 56 h; (2) Denopamine increased alveolar fluid clearance in rats exposed to hyperoxia as well as in rats without exposure to hyperoxia; (3) Denopamine primarily increased amiloride-insensitive alveolar fluid clearance in rats exposed to hyperoxia; (4) The potency of denopamine was similar to that of terbutaline, a selective β2-adrenergic agonist. In summary, denopamine is a potent stimulator of alveolar fluid clearance in rats exposed to hyperoxia.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(denopamine is a potent stimulator of alveolar fluid clearance in hyperoxic rat lungs)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 22 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:102476 HCAPLUS
DOCUMENT NUMBER: 134:131310
TITLE: Preparation of novel multibinding phenolic compounds as β2-adrenergic receptor agonists
INVENTOR(S): Griffin, John H.; Moran, Edmund J.; Choi, Seok-Ki
PATENT ASSIGNEE(S): Advanced Medicine, Inc., USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 31
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964035	A1	19991216	WO 1999-US11804	19990607 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

```
      RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
          ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
          CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 6362371            B1    20020326    US 1999-323937          19990602 <--
CA 2318894            A1    19991216    CA 1999-2318894         19990604 <--
WO 9964031            A1    19991216    WO 1999-US11786         19990604 <--
    W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
        DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
        JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
        MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
        TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
      RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
          ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
          CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9945435            A     19991230    AU 1999-45435           19990604 <--
EP 1003540            A1    20000531    EP 1999-928344          19990604 <--
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, FI
JP 2002517457         T     20020618    JP 2000-553099          19990604 <--
CA 2318055            A1    19991216    CA 1999-2318055         19990607 <--
CA 2318192            A1    19991216    CA 1999-2318192         19990607 <--
CA 2318286            A1    19991216    CA 1999-2318286         19990607 <--
CA 2319068            A1    19991216    CA 1999-2319068         19990607 <--
CA 2319159            A1    19991216    CA 1999-2319159         19990607 <--
CA 2319175            A1    19991216    CA 1999-2319175         19990607 <--
CA 2319496            A1    19991216    CA 1999-2319496         19990607 <--
CA 2319751            A1    19991216    CA 1999-2319751         19990607 <--
CA 2319756            A1    19991216    CA 1999-2319756         19990607 <--
CA 2321170            A1    19991216    CA 1999-2321170         19990607 <--
CA 2321273            A1    19991216    CA 1999-2321273         19990607 <--
WO 9964034            A1    19991216    WO 1999-US11803         19990607 <--
    W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
        DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
        JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
        MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
        TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
      RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
          ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
          CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
WO 9963930            A2    19991216    WO 1999-US11805         19990607 <--
WO 9963930            A3    20000127
    W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
        DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
        KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
        MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
        TR, TT, UA, UG, US, UZ, VN, YU, ZW
      RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
          ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
          CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
WO 9963983            A1    19991216    WO 1999-US12669         19990607 <--
    W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
        DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
        KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
        MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
        TR, TT, UA, UG, US, UZ, VN, YU, ZW
      RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
```

ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 9964038 A1 19991216 WO 1999-US12673 19990607 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 9964041 A1 19991216 WO 1999-US12727 19990607 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 9964042 A1 19991216 WO 1999-US12728 19990607 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 9963933 A2 19991216 WO 1999-US12730 19990607 <--

WO 9963933 A3 20000203

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 9964000 A1 19991216 WO 1999-US12731 19990607 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 9963993 A1 19991216 WO 1999-US12778 19990607 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
WO 9963996 A1 19991216 WO 1999-US12782 19990607 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9944234 A 19991230 AU 1999-44234 19990607 <--
AU 9944265 A 19991230 AU 1999-44265 19990607 <--
AU 9945491 A 19991230 AU 1999-45491 19990607 <--
AU 9945520 A 19991230 AU 1999-45520 19990607 <--
AU 9946727 A 19991230 AU 1999-46727 19990607 <--
AU 9946751 A 19991230 AU 1999-46751 19990607 <--
AU 9946752 A 19991230 AU 1999-46752 19990607 <--
AU 9946754 A 19991230 AU 1999-46754 19990607 <--
AU 9948181 A 19991230 AU 1999-48181 19990607 <--
AU 750366 B2 20020718
EP 1019360 A1 20000719 EP 1999-930123 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1019075 A1 20000719 EP 1999-931748 19990607 <--
EP 1019075 B1 20050824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1080080 A1 20010307 EP 1999-930158 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1083917 A1 20010321 EP 1999-927291 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1083893 A1 20010321 EP 1999-927331 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1083888 A1 20010321 EP 1999-928425 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085887 A2 20010328 EP 1999-928349 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085870 A2 20010328 EP 1999-930157 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1094826 A1 20010502 EP 1999-930156 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1100519 A1 20010523 EP 1999-930155 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1107753 A1 20010620 EP 1999-928457 19990607 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
TR 200003650 T2 20010821 TR 2000-3650 19990607 <--
BR 9910832 A 20011016 BR 1999-10832 19990607 <--

JP	2002517420	T	20020618	JP 2000-553004	19990607	<--
JP	2002517459	T	20020618	JP 2000-553102	19990607	<--
JP	2002517460	T	20020618	JP 2000-553103	19990607	<--
JP	2002517463	T	20020618	JP 2000-553110	19990607	<--
HU	2002001545	A2	20020928	HU 2002-1545	19990607	
HU	2002001545	A3	20030128			
SG	93205	A1	20021217	SG 1999-2843	19990607	
CN	1193788	C	20050323	CN 1999-804188	19990607	
AT	302748	T	20050915	AT 1999-931748	19990607	
ES	2247814	T3	20060301	ES 1999-931748	19990607	
PL	192567	B1	20061130	PL 1999-346411	19990607	
AP	1869	A	20080831	AP 2000-1916	19990607	
CA	2319497	A1	19991216	CA 1999-2319497	19990608	<--
CA	2319643	A1	19991216	CA 1999-2319643	19990608	<--
CA	2319651	A1	19991216	CA 1999-2319651	19990608	<--
CA	2320926	A1	19991216	CA 1999-2320926	19990608	<--
CA	2321120	A1	19991216	CA 1999-2321120	19990608	<--
CA	2321152	A1	19991216	CA 1999-2321152	19990608	<--
WO	9963999	A1	19991216	WO 1999-US12626	19990608	<--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO	9963936	A2	19991216	WO 1999-US12770	19990608	<--
WO	9963936	A3	20000203			
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO	9964052	A1	19991216	WO 1999-US12876	19990608	<--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO	9964053	A1	19991216	WO 1999-US12907	19990608	<--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, BR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO	9964055	A1	19991216	WO 1999-US12994	19990608	<--

WO 9964055 A9 20020829
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
WO 9963944 A2 19991216 WO 1999-US12995 19990608 <--
WO 9963944 A3 20000210
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2319650 A1 19991229 CA 1999-2319650 19990608 <--
WO 9966944 A1 19991229 WO 1999-US12989 19990608 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9943368 A 19991230 AU 1999-43368 19990608 <--
AU 9943376 A 19991230 AU 1999-43376 19990608 <--
AU 9946747 A 19991230 AU 1999-46747 19990608 <--
AU 9952039 A 19991230 AU 1999-52039 19990608 <--
AU 9946776 A 20000110 AU 1999-46776 19990608 <--
EP 1082289 A1 20010314 EP 1999-930185 19990608 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1083921 A1 20010321 EP 1999-955430 19990608 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085889 A2 20010328 EP 1999-928451 19990608 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085847 A2 20010328 EP 1999-928520 19990608 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085868 A1 20010328 EP 1999-930150 19990608 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1085894 A1 20010328 EP 1999-937155 19990608 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1102597 A1 20010530 EP 1999-955431 19990608 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
SG 81994 A1 20010724 SG 1999-2713 19990608 <--

SG	83720	A1	20011016	SG 1999-2715	19990608 <--
SG	83721	A1	20011016	SG 1999-2717	19990608 <--
US	6355805	B1	20020312	US 1999-328192	19990608 <--
JP	2002517442	T	20020618	JP 2000-553068	19990608 <--
TW	252222	B	20060401	TW 1999-88109475	19990608
US	6288055	B1	20010911	US 2000-499476	20000207 <--
ZA	2000003475	A	20011011	ZA 2000-3475	20000711 <--
ZA	2000004083	A	20011112	ZA 2000-4083	20000810 <--
ZA	2000004085	A	20011112	ZA 2000-4085	20000810 <--
ZA	2000004087	A	20011113	ZA 2000-4087	20000810 <--
ZA	2000004084	A	20011119	ZA 2000-4084	20000810 <--
ZA	2000004561	A	20011130	ZA 2000-4561	20000831 <--
ZA	2000004565	A	20011130	ZA 2000-4565	20000831 <--
MX	2000PA09351	A	20020108	MX 2000-PA9351	20000925 <--
US	6713651	B1	20040330	US 2000-674451	20001101
IN	2000CN00724	A	20050304	IN 2000-CN724	20001127
NO	2000006220	A	20010129	NO 2000-6220	20001207 <--
HK	1029535	A1	20060224	HK 2001-100399	20010115
US	20030087306	A1	20030508	US 2001-15534	20011213
US	20040186080	A1	20040923	US 2004-769219	20040130
US	6919482	B2	20050719		
US	20050209275	A1	20050922	US 2005-126124	20050510
US	7105701	B2	20060912		
US	20060183918	A1	20060817	US 2006-401041	20060410
US	7211695	B2	20070501		

PRIORITY APPLN. INFO.:

US 1998-88466P	P	19980608
US 1998-92938P	P	19980715
WO 1999-US11786	W	19990604
US 1999-327044	B1	19990607
WO 1999-US11803	W	19990607
WO 1999-US11804	W	19990607
WO 1999-US11805	W	19990607
WO 1999-US12669	W	19990607
WO 1999-US12673	W	19990607
WO 1999-US12727	W	19990607
WO 1999-US12728	W	19990607
WO 1999-US12730	W	19990607
WO 1999-US12731	W	19990607
WO 1999-US12778	W	19990607
WO 1999-US12782	W	19990607
US 1999-327904	B1	19990608
WO 1999-US12626	W	19990608
WO 1999-US12770	W	19990608
WO 1999-US12876	W	19990608
WO 1999-US12907	W	19990608
WO 1999-US12989	W	19990608
WO 1999-US12994	W	19990608
WO 1999-US12995	W	19990608
US 2000-493462	B1	20000128
US 2000-674451	A1	20001101
US 2004-769219	A1	20040130
US 2005-126124	A1	20050510

OTHER SOURCE(S): MARPAT 134:131310
GI



I



II

AB Methods for preparing novel multibinding phenolic compds., LpXq [where L = a ligand capable of binding to a β2-adrenergic receptor; X = a linker; p = 2-10; q = 1-20], which serve as β2-adrenergic receptor agonists, are disclosed. Preferred ligands are of formula I [R1 = H, (un)substituted alkyl, or a bond linking ligand to linker; R2 = H, aralkyl, acyl, (un)substituted alkyl, cycloalkyl or a bond linking ligand to linker; W = bond, (un)substituted alkylene wherein one or more carbon atoms is optionally replaced by NR3, O, S, SO, SO2, CO, P-alkyl, PO2, OP(O)O or the alkylene optionally links the ligand to a linker with provisions; R3 = H, alkyl, acyl, or bond linking ligand to linker; X = aryl, heteroaryl, heterocyclyl and (un)substituted cycloalkyl wherein each X optionally links the ligand to the linker]. II was prepared from α,α-dihydroxy-4-hydroxy-3-methoxycarbonylacetophenone via condensation with trans-1,4-diaminocyclohexane with subsequent reduction of intermediate imine. In addition, combinatorial arrays of multimeric ligands and methods of assaying the multimeric ligands are embodied by the invention. As β2-adrenergic receptor agonists, the compds. are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis (no data). The title compds. are also useful in the treatment of nervous system injuries and premature labor. Formulations for capsules, tablets, dry power inhaler, suppositories and suspensions are described.

IT 321708-37-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenolic β2-adrenergic receptor agonists)

RN 321708-37-6 HCAPLUS

CN 1,3-Benzenedimethanol, 4-hydroxy-α1-[[[4-[[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenyl]amino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 23 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:93872 HCAPLUS
DOCUMENT NUMBER: 134:157586
TITLE: Use of substances increasing the intracellular content of cyclic AMP or stimulating activity of cyclic AMP binding proteins for the treatment of illnesses of the bladder
INVENTOR(S): Truss, Michael Carsten; Stief, Christian G.; Jonas, Udo; Uckert, Stefan; Becker, Armin J.; Forssmann, Wolf-Georg
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19935209	A1	20010208	DE 1999-19935209	19990727 <--
PRIORITY APPLN. INFO.:			DE 1999-19935209	19990727

AB The invention discloses the use of substances increasing the intracellular concentration of cAMP by direct stimulation of adenyl cyclase activity, associating with β receptors, or inhibiting cAMP-hydrolyzing phosphodiesterases 1, 2, 3, 4, 7, or 8, or stimulate the functional activity of cAMP binding proteins, for the treatment of urinary bladder storage function disturbances (urge symptomatol., urge incontinence, pollakiuria, Nycturia, and detrusor muscle instability). Such substances include e.g. forskolin, L-858051, adenyl cyclase toxin, xamoterol, denopamine, clenbuterol, procaterol, salbutamol, sameterol, formoterol, terbutaline, fenoterol, BRL 37344, ZD 7114, CPG 12177, CL 316243, ICI 215.001, pindolol, IBMX, methoxymethyl-IBMX, vinpocetin, vincamin, HA-588, calmodulin antagonists, EHNA, amrinone, OPC 3698, enoximone, milrinone, Ro 13-6438, siguazodan, HL 725, 8-Br-cGMP, 8-pCPT-cGMP, Sp-8-Br-cGMPS, PET GCMcP, CD-80.633, BRL 30892, SQ 20009, 3-ethyl-1-(4-fluorophenyl)-6-phenyl-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolopyridine, ZK 62711, Ro 20-1724,, RP 73401, RS 25344, SB 2074499, TVX 2706, zardaverine, 8-bromo-cAMP, and Sp-cAMPS.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(substances increasing the intracellular content of cAMP or stimulating activity of cAMP binding proteins for the treatment of illnesses of the bladder)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 24 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:816874 HCAPLUS

DOCUMENT NUMBER: 134:110104

TITLE: Potent, selective aminothiazolidinediones agonists of the human β3 adrenergic receptor

AUTHOR(S): Malamas, Michael S.; Largis, Elwood; Gunawan, Iwan; Li, Zenan; Tillett, Jeffrey; Han, Stella Ching-Hsien; Mulvey, Ruth

CORPORATE SOURCE: Wyeth-Ayerst Research, Inc., Princeton, NJ, 08543-8000, USA

SOURCE: Medicinal Chemistry Research (2000), 10(3), 164-177
CODEN: MCREEB; ISSN: 1054-2523

PUBLISHER: Birkhaeuser Boston

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB A cloned human β3 adrenergic receptor assay was used to identify potent and selective β3 agonists. The thiazolidinedione moiety has

been identified as a new pharmacophore for the human β3 adrenergic receptor. The versatility of the thiazolidinedione pharmacophore was demonstrated in both the arylethanolamine and phenylpropanolamine families of β3 agonists, where potent and selective compds. have been synthesized. Thiazolidinedione I, a potent and selective human β3 agonist, increased thermogenesis and lowered plasma glucose levels in the db/db mice.

IT 321575-09-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminothiazolidinediones as agonists of human β3 adrenergic receptor)

RN 321575-09-1 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 25 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:703123 HCAPLUS

DOCUMENT NUMBER: 133:237673

TITLE: Preparation of phenylethanolamine compounds

INVENTOR(S): Chen, Daimo; Sun, Hongtao; Zeng, Zhongyi; Jiang, Yaozhong

PATENT ASSIGNEE(S): Chengdu Inst. of Organic Chemistry, Chinese Academy of Sciences, Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 25 pp. CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1237574	A	19991208	CN 1998-112034	19980529 <--
PRIORITY APPLN. INFO.:			CN 1998-112034	19980529

OTHER SOURCE(S): CASREACT 133:237673; MARPAT 133:237673

AB Title phenylethanolamine compds. [R1R2C6H3CH(OH)CH2NHR3·HCl; R1, R2 independently = H, OH, NH2, CH2OH, halo, or alkyl; R3 = H, alkyl, C6H5] are prepared by substituting R1R2C6H3COCH2Br with R3NH2 in THF in the presence of triethylamine, separating obtaining R1R2C6H3COCH2NHR3·HCl,

and hydrogenating in the presence of Pd/C or Raney Ni at (-10°)-50°.

IT 59121-17-4P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylethanolamine compds.)

RN 59121-17-4 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L10 ANSWER 26 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:98300 HCAPLUS
DOCUMENT NUMBER: 132:132356
TITLE: Chemically induced intracellular hyperthermia for therapeutic and diagnostic use
INVENTOR(S): Bachynsky, Nicholas; Roy, Woodie
PATENT ASSIGNEE(S): Texas Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006143	A1	20000210	WO 1999-US16940	19990727 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2337690	A1	20000210	CA 1999-2337690	19990727 <--
AU 9951318	A	20000221	AU 1999-51318	19990727 <--
AU 750313	B2	20020718		
EP 1098641	A1	20010516	EP 1999-935949	19990727 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
MX 2001PA01053	A	20030425	MX 2001-PA1053	20010129

AU 2002301502 A1 20030306 AU 2002-301502 20021021
PRIORITY APPLN. INFO.: US 1998-94286P P 19980727
AU 1999-51318 A3 19990727
WO 1999-US16940 W 19990727

AB Therapeutic pharmacol. agents and methods are disclosed for chemical induction of intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy, and other medical conditions. A process and composition are provided for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemical generating heat, and/or free radicals and/or hyperthermia-inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4-dinitrophenol, and their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.

IT 128470-16-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chemical induced intracellular hyperthermia for diagnostic and therapeutic use, and use with other agents)

RN 128470-16-6 HCAPLUS

CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 27 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:37618 HCAPLUS

DOCUMENT NUMBER: 132:317692

TITLE: Selective β2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line

AUTHOR(S): Bando, Takuma; Fujimura, Masaki; Kasahara, Kazuo; Ueno, Toshio; Matsuda, Tamotsu

CORPORATE SOURCE: Department of Respiratory Medicine, Asanogawa General Hospital, Kanazawa, 920-8621, Japan

SOURCE: Oncology Reports (2000), 7(1), 49-52
CODEN: OCRPEW; ISSN: 1021-335X

PUBLISHER: Oncology Reports

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Cisplatin is a key drug in chemotherapy for lung cancer. It has been reported that intracellular accumulation of cisplatin is an important step as a determinant for resistance to cisplatin, which may be modulated by Na+,K+-ATPase activity. And it has been reported that isoproterenol, a β-adrenoceptor agonist, enhances sensitivity to cisplatin in non-small cell lung cancer (NSCLC) cell lines. In this study, the effects of the selective β1, β2, and β3-adrenoceptor agonists on membrane Na+,K+-ATPase activity and sensitivity to cisplatin were evaluated using human non-small cell lung cancer cell line. In the NSCLC cell line, sensitivity to cisplatin was improved by treatment with procaterol, a selective β2-adrenoceptor agonist. Na+,K+-ATPase was activated and intracellular accumulation of cisplatin increased with the treatment. However, β1 or β3-adrenoceptor agonist did not modulate sensitivity to cisplatin or Na+,K+-ATPase activity. These results suggest that β2-adrenoceptor may be one of the determinants for sensitivity to cisplatin in NSCLC. Exogenous β2-adrenoceptor agonists may improve the antitumor effect of chemotherapy involving cisplatin.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of β-adrenoceptor agonists on sensitivity to cisplatin in non-small cell lung cancer cell line)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 28 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:282201 HCAPLUS

DOCUMENT NUMBER: 130:311793

TITLE: Preparation of amides as antidiabetics

INVENTOR(S): Maruyama, Tatsuya; Suzuki, Takayuki; Onda, Kenichi; Hayakawa, Masahiko; Moritomo, Hiroyuki; Kimizuka, Tetsuya; Matsui, Tetsuo

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9920607	A1	19990429	WO 1998-JP4671	19981015	<--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9889288	A	19990506	AU 1998-89288	19981013	<--
AU 736676	B2	20010802			
CA 2305802	A1	19990429	CA 1998-2305802	19981015	<--
CA 2305802	C	20081118			
AU 9894621	A	19990510	AU 1998-94621	19981015	<--
BR 9804500	A	20000411	BR 1998-4500	19981015	<--
EP 1028111	A1	20000816	EP 1998-947894	19981015	<--
EP 1028111	B1	20040512			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
JP 3193706	B2	20010730	JP 2000-516949	19981015	<--
TW 557295	B	20031011	TW 1998-87117145	19981015	
AT 266639	T	20040515	AT 1998-947894	19981015	
PT 1028111	T	20040930	PT 1998-947894	19981015	
ES 2221204	T3	20041216	ES 1998-947894	19981015	
CN 1218045	A	19990602	CN 1998-121375	19981016	<--
CN 1136192	C	20040128			
HU 9802417	A2	19990830	HU 1998-2417	19981016	<--
HU 9802417	A3	20010730			
RU 2186763	C2	20020810	RU 1998-118906	19981016	
PL 196510	B1	20080131	PL 1998-329233	19981016	
US 6346532	B1	20020212	US 2000-529096	20000407	<--
NO 2000001983	A	20000414	NO 2000-1983	20000414	<--
NO 316673	B1	20040329			
PRIORITY APPLN. INFO.:			JP 1997-285778	A 19971017	
			WO 1998-JP4671	W 19981015	

OTHER SOURCE(S): MARPAT 130:311793
GI



I



II

AB The title compds. I [ring B = an optionally substituted heteroaryl optionally fused with a benzene ring; X = a bond, lower alkylene or lower alkenylene (optionally substituted by hydroxy or lower alkyl), carbonyl, or NH (further details related to X are given); A = a lower alkylene or a group represented by (lower alkylene)-O; R1a and R1b = hydrogen or lower alkyl; R2 = hydrogen or halogeno; and Z = nitrogen or CH] are prepared I are useful as diabetes remedies which not only function to accelerate the secretion of insulin and enhance insulin sensitivity but also have an anti-obesity action and an antihyperlipemic action based on their selective stimulative action on β3 receptor. For example, imidazole derivative II was prepared Compds. of this invention significantly decreased blood sugar in mice.

IT 223672-09-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amides as antidiabetics)

RN 223672-09-1 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 29 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:134564 HCAPLUS
DOCUMENT NUMBER: 130:158522
TITLE: Enantiomer separation of drugs by capillary electrophoresis using mixtures of β-cyclodextrin sulfate and neutral cyclodextrins
AUTHOR(S): Izumoto, Shinichi; Nishi, Hiroyuki
CORPORATE SOURCE: Analytical Research Laboratory, Tanabe Seiyaku Co., Ltd., Osaka, 532, Japan
SOURCE: Electrophoresis (1999), 20(1), 189-197
CODEN: ELCTDN; ISSN: 0173-0835
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Direct separation of enantiomers of drugs was investigated by capillary electrophoresis employing mixts. of charged cyclodextrin derivs. (CDs) and elec. neutral CDs (i.e., dual CD system). Among various charged CDs employed, it was found that β-CD sulfate showed relatively wide enantioselectivity for a wide variety of drugs under acidic conditions. Then separation of enantiomers was performed by employing β-CD sulfate and the effect of the addition of elec. neutral CDs to the buffers containing β-CD sulfate was investigated. Through the addition of elec. neutral CDs to the buffers containing the charged CD, resolution of most of the enantiomers was improved, compared with those with the charged CD alone. It was also found that the ring size (α, β, γ), the substitution groups and the concentration of the addnl. elec. neutral CDs affected the enantioselectivity. For example, α-CD addition was effective for the separation of enantiomers of chlorpheniramine and hydroxy-propyl-β-CD was effective for the enantiomer separation of trimetoquinol isomer. The application of the method in optical purity testing is also briefly mentioned.

IT 71771-90-9, Denopamine
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(enantiomer separation of drugs by capillary electrophoresis using mixts. of β-cyclodextrin sulfate and neutral cyclodextrins)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 30 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:625987 HCAPLUS

DOCUMENT NUMBER: 130:323

TITLE: Denopamine, a β1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-α production in the heart

AUTHOR(S): Nishio, Ryosuke; Matsumori, Akira; Shioi, Tetsuo; Wang, Weizhong; Yamada, Takehiko; Ono, Koh; Sasayama, Shigetake

CORPORATE SOURCE: Department of Cardiovascular Medicine, Kyoto University, Kyoto, 606, Japan

SOURCE: Journal of the American College of Cardiology (1998), 32(3), 808-815
CODEN: JACCDI; ISSN: 0735-1097

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This study was designed to examine the effects of denopamine, a selective β1-adrenergic agonist, in a murine model of congestive heart failure (CHF) due to viral myocarditis. Pos. inotropic agents are used to treat severe heart failure due to myocarditis. However, sympathomimetic agents have not been found beneficial in animal models of myocarditis. In vitro: The effects of denopamine on lipopolysaccharide-induced tumor necrosis factor-α (TNF-α) production was studied in murine spleen cells. In vivo: Four-week-old DBA/2 mice were inoculated with the encephalomyocarditis virus (day 0). Denopamine (14 μmol/kg), denopamine (14 μmol/kg) with a selective β1-blocker metoprolol (42 μmol/kg), or denopamine (14 μmol/kg) with metoprolol (84 μmol/kg) was given daily, and control mice received the vehicle only. Survival and myocardial histol. on day 14 and TNF-α levels in the heart on day 6 were examined In the in vitro study, TNF-α levels in treated cells were significantly lower than in controls. In the in vivo study treatment with denopamine significantly improved the survival of the animals (14 of

25 (56%) treated, vs 5 of 25 (20%)control mice), attenuated myocardial lesions, and suppressed TNF-α production (66.5 pg/mg of heart in treated mice vs 113.5 pg/mg of heart in control mice). There was a strong linear relationship between mortality and TNF-α level. These in vitro and in vivo effects of denopamine were significantly inhibited by metoprolol. These results suggest that denopamine may exert its beneficial effects, in part, by suppressing the production of TNF-α via β1-adrenoceptors.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(denopamine prolongs survival in a murine model of congestive heart failure induced by viral myocarditis, suppression of tumor necrosis factor-α production in the heart)

RN 71771-90-9 HCAPLUS
CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 31 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:598282 HCAPLUS
DOCUMENT NUMBER: 130:310
TITLE: Hemodynamic effects of arbutamine
AUTHOR(S): Ogilby, J. David; Molk, Barry; Iskandrian, Ami E.
CORPORATE SOURCE: Division of Cardiology, Department of Medicine, Hahnemann School of Medicine, MCP, Allegheny University of the Health Sciences, Philadelphia, PA, 19102, USA
SOURCE: American Journal of Cardiology (1998), 82(5), 699-702
CODEN: AJCDAG; ISSN: 0002-9149
PUBLISHER: Excerpta Medica, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB This study was designed to examine the effects of arbutamine on central hemodynamics in patients with chest pain syndromes undergoing cardiac catheterization. The relations of hemodynamic changes to myocardial ischemia detected by ST-segment changes and single-photon emission computed tomog. (SPECT) imaging with technetium-99m-sestamibi were also examined Results suggest that i.v. arbutamine, a synthetic catecholamine, produces a balanced inotropic and chronotropic effect in patients with and

without coronary artery disease. Arbutamine may also produce systemic vasodilation, which may be a factor in producing myocardial ischemia in patients with coronary artery disease. This hemodynamic profile is appropriate for an effective pharmacol. stress agent.

IT 128470-16-6, Arbutamine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arbutamine hemodynamic effects in humans with and without coronary artery disease)

RN 128470-16-6 HCAPLUS

CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 32 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:576438 HCAPLUS

DOCUMENT NUMBER: 129:286283

ORIGINAL REFERENCE NO.: 129:58221a,58224a

TITLE: Metabolic response to various β-adrenoceptor agonists in β3-adrenoceptor knockout mice: evidence for a new β-adrenergic receptor in brown adipose tissue

AUTHOR(S): Preitner, Frederic; Muzzin, Patrick; Revelli, Jean-Pierre; Seydoux, Josiane; Galitzky, Jean; Berlan, Michel; Lafontan, Max; Giacobino, Jean-Paul

CORPORATE SOURCE: Departements de Biochimie Medicale, Centre Medical Universitaire, Geneva, CH-1211/4, Switz.

SOURCE: British Journal of Pharmacology (1998), 124(8), 1684-1688
CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Stockton Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The β3-adrenoceptor plays an important role in the adrenergic response of brown and white adipose tissues (BAT and WAT). In this study, in vitro metabolic responses to β-adrenoceptor stimulation were compared in adipose tissues of β3-adrenoceptor knockout and wild type mice. The measured parameters were BAT fragment oxygen uptake (MO2) and isolated white adipocyte lipolysis. In BAT of wild type mice

(-)-norepinephrine maximally stimulated MO2 4.1-fold. Similar maximal stimulations were obtained with β1-,β2- or β3-adrenoceptor selective agonists (dobutamine 5.1, terbutaline 5.3 and CL 316,243 4.8-fold, resp.); in BAT of β3-adrenoceptor knockout mice, the β1- and β2-responses were fully conserved. In BAT of wild type mice, the β1/β2-antagonist and β3-partial agonist CGP 12177 elicited a maximal MO2 response (4.7-fold). In β3-adrenoceptor knockout BAT, this response was fully conserved despite an absence of response to CL 316,243. This unexpected result suggests that an atypical β-adrenoceptor, distinct from the β1-, β2- and β3-subtypes and referred to as a putative β4-adrenoceptor is present in BAT and that it can mediate in vitro a maximal MO2 stimulation. In isolated white adipocytes of wild type mice, (-)-epinephrine maximally stimulated lipolysis 12.1-fold. Similar maximal stimulations were obtained with β1-, β2- or β3-adrenoceptor selective agonists (T0509 12, procaterol 11, CL 316,243 11-fold, resp.) or with CGP 12177 (7.1-fold). In isolated white adipocytes of β3-adrenoceptor knockout mice, the lipolytic responses to (-)epinephrine, to the β1-, β2-, β3-adrenoceptor selective agonists and to CGP 12177 were almost or totally depressed, whereas those to ACTH, forskolin and dibutyryl cAMP were conserved.

IT 96843-99-1, T0509
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(metabolic response to various β-adrenoceptor agonists in β3-adrenoceptor knockout and evidence for new β-adrenergic receptor in brown adipose tissue)

RN 96843-99-1 HCAPLUS

CN 1,2-Benzenediol, 4-[(1R)-2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1-hydroxyethyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 33 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:535771 HCAPLUS
DOCUMENT NUMBER: 129:198012
ORIGINAL REFERENCE NO.: 129:40063a,40066a
TITLE: Preparation of phenethanol derivatives and their use as antidiabetic agents
INVENTOR(S): Maruyama, Tatsuya; Onta, Kenichi; Hayakawa, Akihiko; Matsui, Tetsuo

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10218861	A	19980818	JP 1997-21870	19970204 <--

PRIORITY APPLN. INFO.: JP 1997-21870 19970204
OTHER SOURCE(S): MARPAT 129:198012
GI For diagram(s), see printed CA Issue.
AB The derivs. I [ring B = II, III, IV; X, Y = O, S, NR6; R1 = H, lower alkyl; R2 = H, lower alkyl, NHSO2Me, NHCOR3; R3 = H, lower alkyl, mono- or di(lower alkylamino), aryl, aralkyl; R4, R5 = H, lower alkyl, amino; R6 = H, lower alkyl, aralkyl] or their salts as β3-adrenoceptor agonists are prepared Antidiabetic agents containing I or thir salts as active ingredients are also claimed. I decreased blood glucose of obese and hyperglycemic kk mice with insulin resistance upon both oral and percutaneous administrations. I also increased insulin secretion in normal rats. Preparation of some of I was given.
IT 211636-04-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antidiabetic phenethanol derivs. as β3-adrenoceptor agonists)
RN 211636-04-3 HCAPLUS
CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-4-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L10 ANSWER 34 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:523550 HCAPLUS
DOCUMENT NUMBER: 129:254254
ORIGINAL REFERENCE NO.: 129:51599a
TITLE: Clinical and pharmacological effects of denopamine, an orally active β1 agonist
AUTHOR(S): Habuchi, Yoshizumi; Tanaka, Hideo; Yoshimura, Manabu
CORPORATE SOURCE: Department of Clinical Laboratory and Medicine, Kyoto Prefectural University of Medicine, Kyoto, 602, Japan

SOURCE: Cardiovascular Drug Reviews (1998), 16(1), 62-75
CODEN: CDREEA; ISSN: 0897-5957
PUBLISHER: Neva Press
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 71 refs. Denopamine is a β1-selective agonist developed for the purpose of non-parenteral cardiotonic treatment. This agent shows a pos. inotropic effect with an intrinsic activity of 0.72 to 1.0; it stimulates adenylate cyclase and the L-type Ca2+ current less potently with an intrinsic activity of 0.15 to 0.65. The denopamine-activated β1-adrenoceptor stimulates a particular (non-sarcolemmal) fraction of adenylate cyclase. The resultant compartmentalization of cAMP is probably responsible for the lesser effect of denopamine on membrane ionic currents and heart rate. Thus, denopamine exerts pos. inotropic effects with minimal cAMP formation, only a small increase in myocardial oxygen consumption, and with little desensitization. Denopamine has α1-antagonistic actions on the vascular smooth muscle, and reduces peripheral vascular resistance. Because of these beneficial effects, denopamine administered either i.v. or orally, improves hemodynamic parameters, including peak dP/dt, cardiac output, and left ventricular end diastolic pressure. These effects are attenuated when the drug is used in severe heart failure, due to the preferential down-regulation of β1-adrenoceptors in heart failure and high selectivity of denopamine for β1-adrenoceptors. The usefulness of denopamine in long-term therapy has not yet been demonstrated.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(denopamine clin. and pharmacol. effects in human cardiovascular disease)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 35 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:471470 HCAPLUS
DOCUMENT NUMBER: 129:108907
ORIGINAL REFERENCE NO.: 129:22377a,22380a

10521294

TITLE: Preparation of N-[3-(2-aralkylamino-1-hydroxyethyl)phenyl]methanesulfonamides and analogs as β3 adrenoceptor agonists

INVENTOR(S): Washburn, William N.; Girotra, Ravindar N.; Sher, Philip M.; Mikkilineni, Amarendra B.; Poss, Kathleen M.; Mathur, Arvind; Bisacchi, Gregory S.; Gavai, Ashvinikumar V.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: U.S., 79 pp., Cont.-in-part of U. S. Ser. No. 171,285, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5776983	A	19980707	US 1994-346543	19941202 <--
TW 424082	B	20010301	TW 1994-83111890	19941219 <--
HU 72302	A2	19960429	HU 1994-3694	19941220 <--
HU 220063	B	20011028		
CA 2138675	A1	19950622	CA 1994-2138675	19941221 <--
CA 2138675	C	20070501		
FI 9406003	A	19950622	FI 1994-6003	19941221 <--
NO 9404969	A	19950622	NO 1994-4969	19941221 <--
AU 9481635	A	19950629	AU 1994-81635	19941221 <--
AU 688417	B2	19980312		
JP 07206806	A	19950808	JP 1994-336251	19941221 <--
CN 1109050	A	19950927	CN 1994-113297	19941221 <--
ZA 9410213	A	19960621	ZA 1994-10213	19941221 <--
AT 235463	T	20030415	AT 1994-120281	19941221
ES 2194857	T3	20031201	ES 1994-120281	19941221

PRIORITY APPLN. INFO.: US 1993-171285 B2 19931221
OTHER SOURCE(S): MARPAT 129:108907
GI



I

AB R1SO2NHZ1CH(OH)CHR6NHCR3R4Z2R2 [R1 = alkyl or aryl(alkyl); R2 = (un)substituted Ph; R3 = H, alkyl, heterocyclyl, etc.; R4 = H, alkyl, etc.; R6 = H or alkyl; Z1 = (un)substituted 1,3-phenylene; Z2 = bond,

Updated Search

(acyl)methylene, (CH2)2-3] were prepared as β3 adrenoceptor agonists (no data). Thus, 3,4-(MeO)2C6H3CH(NH2)CH2Ph was N-alkylated by 4,3-(PhCH2O)(MeSO2NH)C6H3COCH2Br (preparation each given) to give, after hydrogenation, title compound I.

IT 170685-93-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[3-(2-aralkylamino-1-hydroxyethyl)phenyl]methanesulfonamides and analogs as β3 adrenoceptor agonists)

RN 170685-93-5 HCAPLUS

CN Benzoic acid, 4-[[[5-[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]amino]sulfonyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 36 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:394314 HCAPLUS
DOCUMENT NUMBER: 129:81737
ORIGINAL REFERENCE NO.: 129:16877a,16880a
TITLE: Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same
INVENTOR(S): Shibasaki, Masakatsu; Sasai, Hiroaki; Urata, Yasuo; Fujita, Mamoru
PATENT ASSIGNEE(S): Chisso Corporation, Japan
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824753	A1	19980611	WO 1997-JP4240	19971120 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,

GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9749679	A	19980629	AU 1997-49679		19971120 <--
EP 947498	A1	19991006	EP 1997-912527		19971120 <--
EP 947498	B1	20040915			
R: CH, DE, FR, GB, LI					
US 6632955	B1	20031014	US 1999-319135		19990901
US 20020193447	A1	20021219	US 2002-188888		20020705
US 20050148801	A1	20050707	US 2005-44223		20050128
US 7205425	B2	20070417			
US 20070060656	A1	20070315	US 2006-595987		20061113
PRIORITY APPLN. INFO.:			JP 1996-336425	A	19961202
			WO 1997-JP4240	W	19971120
			US 1999-319135	A3	19990901
			US 2002-188888	A3	20020705
			US 2005-44223	A3	20050128

OTHER SOURCE(S): CASREACT 129:81737; MARPAT 129:81737

GI



I



II

AB Optically active 1-(substituted phenyl)-2-nitro alc. derivs. represented by general formula (I; R = NO2; n and m are integers satisfying the relationship 0<n+m≤5; R1, R2 = H or HO-protecting group; when n+m≥2, R1 and R2 stand alone by themselves or R1 its self, R2 its self or R1 and R2 form a ring; R3 = (CH2)l (wherein l = 0, 1, 2, 3); R4 = H, alkyl, hydroxymethyl; * represents the optically active site; when R4 = H, * is absent since the optically activity of the site attached to R4 is lost) and 1-(substituted phenyl)-2-amino alc. derivs. represented by general formula I (R = NH2) are stereoselectively prepared via addition (nitroaldol) reaction of aldehydes (II; R1 - R4, l, m, n = same as above) with nitroalkanes represented by formula R4CH2NO2 (R4 = same as above) in the presence of a rare earth metal complex possessing optically active ligands. For example, (R)-arbutamine and (R)-salmeterol, which are useful as a bronchodilator, can be synthesized from the compds. represented by formula I through the optically active amino alcs. represented by formula II, i.e. (-)-[3,4-bis(tert-butyldimethylsilyloxy)phenyl]-2-aminoethanol and 2,2-dimethyl-α-aminomethyl-1,3-benzodioxane-6-methanol (III), resp., and useful as an intermediate for pharmaceuticals. Thus, 2,2-dimethyl-1,3-benzodioxane-6-acetaldehyde was dissolved in THF at -40°, mixed with a solution of a rare earth metal complex prepared by reacting (S)-6,6'-bis(triethylsilylethynyl)-1,1'-dihydroxy-2,2'-binaphthalene, Sm(Oi-Pr)3, and BuLi in THF, and stirred for 30 min. To the resulting mixture was added dropwise MeNO2 and the mixture was stirred for 61 h to give 86% 2,2-dimethyl-α-nitromethyl-1,3-benzodioxane-6-

methanol of 87% e.e. which was hydrogenated over 10% Pd-C to give (-)-III. Reductive amination of (-)-III with 6-(1-phenylbutoxy)hexaldehyde followed by acid hydrolysis gave (R)-salmeterol.

IT 128470-16-6P, Arbutamine
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of optically active nitro alc. and amino alc. derivs. by stereoselective addition reaction of aldehydes with nitroalkanes)

RN 128470-16-6 HCAPLUS
CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 37 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:656158 HCAPLUS
DOCUMENT NUMBER: 127:303106
ORIGINAL REFERENCE NO.: 127:59095a,59098a
TITLE: Direct comparison of arbutamine and dobutamine stress testing with myocardial perfusion imaging and echocardiography in patients with coronary artery disease
AUTHOR(S): Shehata, Adel R.; Ahlberg, Alan W.; Gillam, Linda D.; Mascitelli, Victor A.; Piriz, Jose M.; Fleming, Rene A.; Chen, Chunguang; Waters, David D.; Heller, Gary V.
CORPORATE SOURCE: Nuclear Cardiology & Echocardiography Lab., Div. Cardiology, Hartford Hospital, Hartford, CT, USA
SOURCE: American Journal of Cardiology (1997), 80(6), 716-720
CODEN: AJCDAG; ISSN: 0002-9149
PUBLISHER: Excerpta Medica
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Arbutamine, a new sympathomimetic compound, appears to elicit a more balanced inotropic and chronotropic response than dobutamine, currently used as a pharmacol. stress agent. The present study was performed to compare standard dobutamine stress testing with arbutamine for the detection of myocardial ischemia with technetium (Tc)-99m sestamibi tomog. imaging and 2-dimensional echocardiog. in patients with coronary artery disease. Twenty-six patients with evidence of coronary artery disease underwent dobutamine infusion of 5 to 40 μg/kg/min in 3-min stages. On a sep.

day, arbutamine was administered by an automated, computerized, closed-loop device monitoring both heart rate and blood pressure. Both infusions were terminated upon achievement of target heart rate, completion of maximal infusion dose (dobutamine), heat rate saturation (arbutamine), or standard clin. end points. Tc-99m sestamibi was injected before termination of both infusions followed by tomog. myocardial perfusion imaging, whereas echocardiog. was performed at baseline and throughout the infusions. There were no significant differences in maximal heart rate, blood pressure, and rate-pressure product as well as in the development of anginal symptoms or electrocardiog. changes during both infusions. The location and severity of myocardial perfusion defects and echocardiog. wall motion abnormalities were similar between both agents. It is concluded that arbutamine produces similar imaging results compared with standard dobutamine stress with both Tc-99m sestamibi single-photon emission computed tomog. myocardial perfusion imaging and 2-dimensional echocardiog.

IT 128470-16-6, Arbutamine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(direct comparison of arbutamine and dobutamine stress testing with myocardial perfusion imaging and echocardiog. in humans with coronary artery disease)

RN 128470-16-6 HCAPLUS
CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 38 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:393430 HCAPLUS
DOCUMENT NUMBER: 127:92395
ORIGINAL REFERENCE NO.: 127:17705a,17708a
TITLE: Arbutamine stress echocardiography
AUTHOR(S): Ketteler, T.; Krahwinkel, W.; Wolfertz, J.; Goedke, J.; Hoffmeister, T.; Scheuble, L.; Guelker, H.
CORPORATE SOURCE: Wuppertal Heart Center, Department of Cardiology, University of Witten/Herdecke, Wuppertal, Germany
SOURCE: European Heart Journal (1997), 18(Suppl. D), D24-D30
CODEN: EHJODF; ISSN: 0195-668X

PUBLISHER: Saunders
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Arbutamine, a new potent non-selective β-adrenoceptor agonist with mild ai-sympathomimetic activity, has been developed specifically for pharmacol. stress testing. The drug acts like phys. exercise, increasing both heart rate and myocardial contractility. Sensitivity, specificity and accuracy in detecting significant stenotic coronary artery disease are 76%, 96%, and 82%, resp., again similar to those of exercise echocardiog. The drug is delivered by a computerized drug delivery and monitoring device (GenESA) which adjusts the infusion rate according to the patient's heart rate data feedback. The drug is generally well tolerated and has an acceptable safety profile. This article describes recent clin. experience with arbutamine and presents preliminary results of a multicenter multinational study which evaluates the clin. utility and safety of the GenESA system in diagnosing coronary artery disease.

IT 128470-16-6, Arbutamine
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arbutamine stress echocardiog.)

RN 128470-16-6 HCAPLUS

CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 39 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:247585 HCAPLUS
DOCUMENT NUMBER: 126:334492
ORIGINAL REFERENCE NO.: 126:64937a
TITLE: Separation of the enantiomers of basic drugs by affinity capillary electrophoresis using a partial filling technique and α1-acid glycoprotein as chiral selector
AUTHOR(S): Tanaka, Y.; Terabe, S.
CORPORATE SOURCE: Department Analytical Chemistry, Nippon Boehringer Ingelheim Co. Ltd., Kawanashi, 666, Japan
SOURCE: Chromatographia (1997), 44(3/4), 119-128
CODEN: CHRGB7; ISSN: 0009-5893
PUBLISHER: Vieweg
DOCUMENT TYPE: Journal

LANGUAGE: English
AB Separation of the enantiomers of a variety of basic drugs by affinity capillary electrophoresis was investigated using α1-acid glycoprotein (α1-AGP) as chiral selector. To use a high concentration of α1-AGP without causing low detection sensitivity, the partial filling technique was employed. Enantiomer sepns. were performed under conditions (a running buffer at pH 5.0 or 6.0) causing the protein to migrate toward the injection end. 29 Basic racemates were successfully separated by optimizing the protein concentration, buffer pH, and organic modifier. α1-AGP obtained from 3 different suppliers was used to investigate differences among the proteins from different sources. Although most of the racemates were similarly separated with any of the 3 types of α1-AGP, some racemates, e.g. acebutolol behaved differently with the 3 types. The reasons for the different enantioselectivities of the 3 types of α1-AGP was not yet clarified. The method was used to test the optical purity of com. sulpiride enantiomers and the method was suitable and applicable for this purpose.
IT 71771-90-9, Denopamine
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(separation of enantiomers of basic drugs by affinity capillary electrophoresis using α1-acid glycoprotein as chiral selector)
RN 71771-90-9 HCAPLUS
CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 40 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:35306 HCAPLUS
DOCUMENT NUMBER: 126:69924
ORIGINAL REFERENCE NO.: 126:13393a,13396a
TITLE: Influence of hypoxia on hemodynamic effect of docarpamine: an experimental study
AUTHOR(S): Amitani, Shigeru; Kurose, Mitsurou; Sohara, Hiroshi; Miyahara, Kenkichi; Kakura, Hideaki; Murakami, Takuya; Nozaki, Shusaku; Sakamoto, Hiroshi
CORPORATE SOURCE: Cardiovascular Div., Shinkyo Hospital, Japan
SOURCE: Kokyu to Junkan (1996), 44(11), 1195-1200
CODEN: KOJUA9; ISSN: 0452-3458
PUBLISHER: Igaku Shoin
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
AB The influence of hypoxia on hemodynamic effect of docarpamine (DCP) was

compared with that of denopamine (DNOP), exptl. Results obtained from these expts. were as follows;(1) Although the pos. inotropic action of DCP did not appear significantly in hypoxia, the vasodilating effect was maintained as well as in normoxia. (2) DNOP produced both an apparent pos. inotropic action and a significant pos. chronotropic action even in hypoxia, and also revealed slight vasodilating effect. (3) Although DCP had similar effects to DNOP on basic pharmacol. characteristics, there were different effects between two drugs in hypoxia. Namely, despite the affection of the inotropic action of DCP by the acidosis, it maintained cardiac output without increase of heart rate combined with its vasodilating effect.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hypoxia influence on hemodynamic effect of docarpamine)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 41 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1997:24244 HCAPLUS
DOCUMENT NUMBER:	126:113066
ORIGINAL REFERENCE NO.:	126:21709a,21712a
TITLE:	Prolongation of the life span of cardiomyopathic hamster by the adrenergic β1-selective partial agonist denopamine
AUTHOR(S):	Kurosawa, Hideo; Narita, Hiroshi; Kaburaki, Minako; Yabana, Hideo; Doi, Hisayoshi; Itogawa, Emiko; Okamoto, Masahito
CORPORATE SOURCE:	Lead Optimization Research Laboratory, Tanabe Selyaku Co., Ltd., Saitama, 335, Japan
SOURCE:	Japanese Journal of Pharmacology (1996), 72(4), 325-333 CODEN: JJPAAZ; ISSN: 0021-5198
PUBLISHER:	Japanese Pharmacological Society
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB Influence of cardiotonic agents on the prognosis of heart failure depends on the individual therapeutic agents, and favorable and unfavorable effects of these agents have been reported in clin. trials. The authors studied the effect of the cardiotonic agent denopamine on the life span of

cardiomyopathic hamsters (BIO 14.6 strain) in the heart failure period. Non-treated hamsters started to die at 40 wk of age, and their survival rate decreased to 23.8% at the age of 65 wk. Hamsters treated with denopamine (400 ppm in diet) from 36 wk of age did not die until the age of 52 wk, except in cases of accidental death. The survival rate of this group at 65 wk of age was about 40%. Survival rates of these 2 groups were significantly different when animals with accidental death were excluded. To elucidate the mechanism of the effect of denopamine, the authors performed several expts. after dietary treatment with denopamine for 4 to 6 wk from 37 wk of age. Denopamine treatment lowered plasma levels of noradrenaline and dopamine, but affected neither the cardiac contractility nor the β-adrenoceptor d. In summary, denopamine significantly decreases the mortality of cardiomyopathic hamsters. Its effect to lower the plasma catecholamine levels may be responsible for the beneficial effect of denopamine.

IT 71771-90-9, Denopamine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prolongation of the life span of cardiomyopathic hamster by the adrenergic β1-selective partial agonist denopamine)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 42 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:616601 HCAPLUS
DOCUMENT NUMBER: 125:275666
ORIGINAL REFERENCE NO.: 125:51553a,51556a
TITLE: Preparation of pyridyl-substituted sulfonamides as selective β3 adrenergic receptor agonists for the treatment of type II diabetes and obesity
INVENTOR(S): Fisher, Michael H.; Naylor, Elizabeth M.; Ok, Dong; Weber, Ann E.; Shih, Thomas; Ok, Hyun
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 35 pp., Cont.-in-part of U. S. Ser. No. 404,565, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5561142	A	19961001	US 1995-445630	19950522 <--
US 5705515	A	19980106	US 1996-684901	19960725 <--
PRIORITY APPLN. INFO.:			US 1994-233166	B2 19940426
			US 1995-404565	B2 19950321
			US 1995-445630	A2 19950522
OTHER SOURCE(S):		MARPAT 125:275666		

GI



I



II

AB The title compds. [I; A = pyridinyl; R1 = OH, O, halo, etc.; R2, R3 = H, C1-10 alkyl, C1-10 alkoxy, etc.; X = CH2, (CH2)2, CH:CH, CH2O; R4, R5 = H, C1-10 alkyl, halo, etc.; R6 = H, C1-10 alkyl; R7 = (substituted) Ph, naphthyl, a 5- or 6-membered heterocyclic ring, etc.; n = 0-5; m = 0-1; r = 0-3], selective β3 adrenergic receptor agonists and therefore useful in the treatment of type II diabetes and obesity as well as neurogenic inflammation, depression, gastrointestinal disorders, gut motility and as lowering triglyceride and cholesterol levels agents, were prepared by coupling an aminoalkylphenylsulfonamide with an appropriately substituted epoxide. Thus, refluxing (R)-(pyrid-3-yl)oxirane with N-[4-(2-aminoethyl)phenyl]-4-[5-(3-cyclopentylpropyl)[1,2,4]-oxadiazol-3-yl]benzenesulfonamide in dry MeOH afforded the desired product (R)-II. Compds. I were effective at 0.07-350 mg/day when treating diabetes mellitus and/or hyperglycemia.

IT 173902-22-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridyl-substituted sulfonamides as selective β3 adrenergic receptor agonists for the treatment of type II diabetes and obesity)

RN 173902-22-2 HCAPLUS

CN Benzenesulfonamide, N-[4-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]phenyl]-4-iodo-, (R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 173902-21-1
CMF C22 H23 I N2 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L10 ANSWER 43 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1996:494735 HCAPLUS
DOCUMENT NUMBER:	125:221588
ORIGINAL REFERENCE NO.:	125:41417a,41420a
TITLE:	Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
INVENTOR(S):	Fisher, Michael H.; Naylor, Elizabeth M.; Weber, Ann E.
PATENT ASSIGNEE(S):	Merck and Co., Inc., USA
SOURCE:	U.S., 29 pp., Cont.-in-part of U.S. Ser. No. 233,166,abandoned. CODEN: USXXAM
DOCUMENT TYPE:	Patent

10521294

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 5541197	A	19960730	US 1995-404566	19950321	<--
IL 113410	A	19991130	IL 1995-113410	19950418	<--
CA 2187932	A1	19951102	CA 1995-2187932	19950421	<--
WO 9529159	A1	19951102	WO 1995-US4956	19950421	<--
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, US, UZ					
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9523937	A	19951116	AU 1995-23937	19950421	<--
AU 687558	B2	19980226			
EP 757674	A1	19970212	EP 1995-917116	19950421	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
CN 1149869	A	19970514	CN 1995-192821	19950421	<--
HU 76442	A2	19970929	HU 1996-2951	19950421	<--
JP 09512275	T	19971209	JP 1995-527797	19950421	<--
JP 3149186	B2	20010326			
ZA 9503336	A	19960109	ZA 1995-3336	19950425	<--
FI 9604314	A	19961025	FI 1996-4314	19961025	<--
NO 9604548	A	19961223	NO 1996-4548	19961025	<--
PRIORITY APPLN. INFO.:			US 1994-233166	B2 19940426	
			US 1995-404565	A 19950321	
			US 1995-404566	A 19950321	
			WO 1995-US4956	W 19950421	

OTHER SOURCE(S): MARPAT 125:221588
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Substituted sulfonamides I wherein: n is 0-5; m is 0 or 1; p is 0-3; ring A is (1) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, (2) a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, (3) a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen fused to a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, (4) Ph, or (5) a benzene ring fused to a C3-8 cycloalkyl ring; R1 is, e.g., OH, oxo, halo; R2 and R3 are independently (1) hydrogen, (2) C1-C10 alkyl or (3) C1-C10 alkyl with 1 to 4 substituents selected from hydroxy, C1-C10 alkoxy, and halogen; X is(1) CH2, (2) CH2CH2, (3) CH:CH, or (4) CH2O; R4 and R5 are independently , e.g., hydrogen, C1-C10 alkyl, halogen; R6 is (1) hydrogen or (2) C1-C10 alkyl; R7 is Z-(R1a)n; R1a is, e.g., R1 (with proviso), C3-8 cycloalkyl, optionally substituted Ph; Z is, e.g., Ph, naphthyl, heterocyclic, are selective β3 adrenergic receptor agonists with very little β1 and β2 adrenergic receptor activity and as such the compds. are

capable of increasing lipolysis and energy expenditure in cells (no data). The compds. thus have potent activity in the treatment of Type II diabetes and obesity. The compds. can also be used to lower triglyceride levels and cholesterol levels or raise high d. lipoprotein levels or to decrease gut motility. In addition, the compds. can be used to reduced neurogenic inflammation or as antidepressant agents. Compns. and methods for the use of the compds. in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high d. lipoprotein levels or for increasing gut motility are also disclosed. Thus, e.g., ring cleavage of (R)-2-(tetrazolo[1,5-a]pyrid-6-yl)oxirane with 2-(4-aminophenyl)ethylamine followed by Boc protection afforded amino alc. II; chlorosulfonylation of N-hexyl-N'-phenylurea (from hexylamine + Ph isocyanate) provided N-hexyl-N'-(4-chlorosulfonylphenyl)urea III; coupling of II + III followed by deprotection afforded sulfonamide IV.

IT 173900-55-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity)

RN 173900-55-5 HCAPLUS

CN Benzenesulfonamide, N-[4-[2-[[2-(4-amino-3,5-dichlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-4-[[(hexylamino)carbonyl]amino]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NH—$(CH_2)_5$—Me

L10 ANSWER 44 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:430104 HCAPLUS
DOCUMENT NUMBER: 125:132141
ORIGINAL REFERENCE NO.: 125:24453a,24456a
TITLE: ATP-sensitive K+ channel opener pinacidil augments β1-adrenoceptor-induced coronary vasodilation in dogs
AUTHOR(S): Katsuda, Yousuke; Egashira, Kensuke; Ueno, Hideki; Arai, Yukinori; Akatsuka, Yutaka; Kuga, Takeshi; Shimokawa, Hiroaki; Takeshita, Akira

CORPORATE SOURCE: Res. Inst. Angiocardiol. Cardiovascular Clinic, Kyushu Univ. Sch. Med., Fukuoka, 812-82, Japan
SOURCE: American Journal of Physiology (1996), 270(6, Pt. 2), H2210-S2215
CODEN: AJPHAP; ISSN: 0002-9513
PUBLISHER: American Physiological Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The opening of ATP-sensitive K+ (KATP+) channels contributes to the mechanism of metabolic coronary vasodilation. The aim of the present study was to determine whether KATP+ channel opener pinacidil augments coronary vasodilation induced by β-adrenoceptor stimulation. In anesthetized dogs, coronary vasodilation in response to intracoronary infusion of a β1-adrenoceptor agonist denopamine, selective β2-adrenoceptor stimulation with isoproterenol after bisoprolol or nitroglycerin was studied before and during simultaneous intracoronary infusion of pinacidil at a dose of 1 μg/min, which had no effect on basal hemodynamics. Pinacidil augmented the denopamine-induced increase in coronary blood flow (CBF) from 38 to 66% but did not affect the denopamine-induced increase in myocardial oxygen consumption (M.ovrhdot.VO2). Pinacidil had no effect on the increases in CBF or M.ovrhdot.VO2 induced by isoproterenol or nitroglycerin. Thus pinacidil selectively augmented β1-adrenoceptor-mediated coronary vasodilation. These observations suggest that the KATP+ channel opener pinacidil may increase myocardial perfusion during metabolic stress associated with β1-adrenoceptor stimulation.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ATP-sensitive K+ channel opener pinacidil augments coronary vasodilation induced by β1-adrenoceptor agonist denopamine in dogs)

RN 71771-90-9 HCAPLUS
CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 45 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:266979 HCAPLUS
DOCUMENT NUMBER: 124:331421
ORIGINAL REFERENCE NO.: 124:61137a,61140a
TITLE: Arbutamine: a novel catecholamine for pharmacologic

diagnosis of coronary disease
AUTHOR(S): Young, Mark; Valcke, Christopher; Mullane, Kevin; Gardiner, Peter
CORPORATE SOURCE: Gensia, Inc., San Diego, CA, 92121, USA
SOURCE: Cardiovascular Drug Reviews (1995), 13(4), 379-98
CODEN: CDREEA; ISSN: 0897-5957
PUBLISHER: Neva Press
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review, with 56 refs., discussing the in vitro and in vivo pharmacol. of arbutamine, studies in animal models of ischemia, the computerized delivery system, and data from clin. experience using the GenESA system.
IT 128470-16-6, Arbutamine
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(arbutamine - a novel catecholamine for pharmacol. diagnosis of coronary disease)
RN 128470-16-6 HCAPLUS
CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 46 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:209937 HCAPLUS
DOCUMENT NUMBER: 124:242363
ORIGINAL REFERENCE NO.: 124:44693a,44696a
TITLE: Stable pharmaceutical lipid emulsions containing oils and emulsifiers and lecithins
INVENTOR(S): Suzuki, Hidekazu; Yamazaki, Satoshi; Naito, Yoshikazu; Endo, Kenji; Oguma, Touru; Maeda, Makoto
PATENT ASSIGNEE(S): Wakamoto Pharmaceutical Co., Ltd., Japan
SOURCE: Can. Pat. Appl., 77 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

CA 2153553	A1	19960114	CA 1995-2153553		19950710 <--
US 5693337	A	19971202	US 1995-500087		19950710 <--
EP 700678	A1	19960313	EP 1995-110923		19950712 <--
R: DE, FR, GB, IT					
JP 08081360	A	19960326	JP 1995-197896		19950712 <--
PRIORITY APPLN. INFO.:			JP 1994-183045	A	19940713

AB A lipid emulsion which comprises (A) an oil component, (B) an emulsifying agent containing yolk lecithin and/or soybean lecithin, and (C) water, wherein the lipid emulsion further comprises citric acid or a pharmaceutically acceptable salt thereof and at least one member selected from the group consisting of methionine, phenylalanine, serine, histidine and pharmaceutically acceptable salts thereof, provided that is does not simultaneously contain methionine and phenylalanine. The emulsion does not change of color and formation of oil drops associated with the conventional natural lecithin-containing lipid emulsions due to the synergistic effect of the foregoing additives. The drug containing lipid emulsion is also excellent in storage stability and thus the foregoing lipid emulsion can be applied to drugs such as injections, eye drops, nasal drips, lotions or liniments, inhalants and drugs for oral administration or cosmetics such as humectants. A solution of 0.012 g of fluorometholone in 20 mL of ethanol was added to a solution of 20 mL hexane:ethanol (10:1) containing 0.54 g of yolk lecithin and 0.06 g of yolk phosphatidylethanolamine and mixed, followed by evaporation of solvent to obtain a lipid film. To the lipid film was added 5.4 g of soybean oil and 94 mL of 2% glycerin aqueous solution followed by vigorous stirring through shaking to carry out preliminary emulsification. The preliminarily emulsified liquid was passed through microfluidizer 10 times under a pressure of 750 kg/cm2 to emulsify the liquid, the pH value of the emulsified liquid was adjusted to 6.5-7.5 to give a milk white stock lipid emulsion.

IT 71771-90-9, Denopamine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable pharmaceutical lipid emulsions containing oils and emulsifiers and lecithins)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 47 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:126835 HCAPLUS
DOCUMENT NUMBER: 124:219857

ORIGINAL REFERENCE NO.: 124:40349a,40352a
TITLE: Prevention of myocardial damage in BIO 14.6 strain of cardiomyopathic hamsters by denopamine
AUTHOR(S): Sutani, Toshio
CORPORATE SOURCE: 1st Dep. Intern. Med., Nara Med. Univ., Kashihara, 634, Japan
SOURCE: Nara Igaku Zasshi (1995), 46(5), 389-96
CODEN: NAIZAM; ISSN: 0469-5550
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effects of denopamine on myocardial damage were studied in BIO hamsters as animal model of human idiopathic cardiomyopathy. They were divided into 2 groups: one that received denopamine treatment (1 mg/kg/day) from 2 mo of age, and a control (untreated) group. Morphol. studies of the myocardium, assays for β-adrenergic receptors, and measurements of myocardial adenylate cyclase (AC) activity and cAMP concentration were performed at 1, 3, and 7 mo of age in all animals. Denopamine inhibited the progression of disease from the stage of hypertrophy to that of congestive failure that was demonstrated in the control BIO hamster. Denopamine inhibited the down-regulation of β-1-adrenergic receptors in the myocardium of the control BIO hamsters at 7 mo of age, and prevented an increase in myocardial AC activity and cAMP concentration that was seen in control BIO hamsters at 3 mo of age (stage of early hypertrophy). Thus, denopamine may prevent myocardial damage in BIO hamsters by inhibiting the down-regulation of β-1-adrenergic receptors, and preventing an increase in myocardial AC activity and cAMP concentration

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prevention of myocardial damage in cardiomyopathic hamsters by denopamine and its mechanism)

RN 71771-90-9 HCAPLUS
CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 48 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:94552 HCAPLUS
DOCUMENT NUMBER: 124:194133
ORIGINAL REFERENCE NO.: 124:35639a,35642a
TITLE: Comparison of the profiles of agonists as stimulants

of the β3-adrenoceptor in vitro with their gastroprotective effects in the conscious rat

AUTHOR(S): Bahl, A. K.; Clayton, N. M.; Coates, J.; Martin, D. P.; Oakley, I. G.; Strong, P.; Trevethick, M. A.

CORPORATE SOURCE: Glaxo Wellcome Research & Development Ltd., Glaxo Wellcome Medicines Research Centre, Stevenage, Herts, SG1 2NY, UK

SOURCE: British Journal of Pharmacology (1996), 117(3), 580-6
CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Stockton

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This paper compares the activity of a range of agonists as stimulants of the β3-adrenoceptor in rat isolated esophagus with their ability to afford protection against indomethacin-induced gastric damage in the conscious rat. The β3-adrenoceptor agonists, CL 316243 and BRL 37344, the non-selective β-adrenoceptor agonist, isoprenaline and the selective β2-adrenoceptor agonist, salmeterol, all evoked concentration-dependent relaxation of precontracted muscularis mucosa from rat esophagus. The rank order of agonist potency was BRL 37344 > CL 316243 > isoprenaline » salmeterol. The selective β1-adrenoceptor agonist, denopamine, did not relax the preparation The relaxant responses to all agonists were resistant to blockade by atenolol (10 μM), and ICI 118551 (1 μM) thus suggesting that they were not mediated by either β1- or β2-adrenoceptor stimulation. In contrast, cyanopindolol and propranolol did inhibit responses to BRL 37344, CL 316243 and isoprenaline, giving pA2 values or pKB ests. which were consistent with an interaction of β3-adrenoceptors (i.e. approx. 8.0 and 6.5 resp.). However, responses to salmeterol were resistant to blockade by all the antagonists tested, which suggests that the high (>1 μM) concns. of salmeterol used exerted non-specific relaxant effects. The agonist effects of CL 316243 and BRL 37344 on β1- and β2-adrenoceptors were assessed on guinea-pig right atrium and precontracted trachea resp. Both agonists had minimal activity as stimulants of heart rate, but did relax trachea, being 380 (CL 316243) and 21 (BRL 37344) fold less potent than isoprenaline. CL 316243 and BRL 37344 were potent inhibitors of indomethacin-induced gastric antral ulceration in the conscious rat (ED50 values = 0.24 and 0.09 μmol kg-1 p.o.) ABA: Salmeterol was approx. 100 times less potent than BRL 37344 as a gastroprotective agent and denopamine was without effect. The gastroprotective effects of CL 316243 and BRL 37344 were resistant to blockade by ICI 118551 (10 mg kg-1, p.o.) and propranolol (10 mg kg-1 p.o.). In contrast, both antagonists caused dose-related inhibition of the protective action of salmeterol (10 mg kg-1, p.o.). Cyanopindolol was not assessed as an antagonist in vivo because preliminary expts. revealed that it exacerbated indomethacin-induced gastric damage in its own right. In conclusion, the β3-adrenoceptor agonists CL 316243 and BRL 37344 were potent inhibitors of indomethacin-induced gastric antral ulceration in the rat. These data suggest that an agonist which is potent and selective for the human β3-adrenoceptor may confer mucosal protection in man.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparison of profiles of agonists as stimulants of

β3-adrenoceptor in vitro with gastroprotective effects in conscious rat)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 49 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:5709 HCAPLUS

DOCUMENT NUMBER: 124:76072

ORIGINAL REFERENCE NO.: 124:13917a,13920a

TITLE: Desensitization and selective down-regulation of rat cardiac β1-adrenoceptors by prolonged in vivo infusion of T-0509, a β1-adrenoceptor full agonist

AUTHOR(S): Sato, Yoji; Adachi-Akahane, Satomi; Prados, Pablo; Imai, Kazuhiro; Nagao, Taku

CORPORATE SOURCE: Dep. Toxicology, Pharmacology, Dep. Analytical Chem., Fac. Pharm. Sci., Univ. Tokyo, Tokyo, 113, Japan

SOURCE: Japanese Journal of Pharmacology (1995), 69(4), 343-50
CODEN: JJPAAZ; ISSN: 0021-5198

PUBLISHER: Japanese Pharmacological Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors studied the effects of prolonged infusion of a selective β1-adrenoceptor (β1AR) full agonist, T-0509 [(-)-(R)-1-(3,4-dihydroxyphenyl)-2-[(3,4-dimethoxyphenethyl)amino]ethanol hydrochloride], with regard to its inotropic effect in vivo and cardiac βAR d. The results were compared with those for isoproterenol. Continuous infusion of isoproterenol at doses of 2.5-40 μg/Kg/h, s.c. for 6 days shifted the dose-response curves of isoproterenol (i.v.) for LVdP/dtmax to the right and increased the ED50 values up to fourfold. Isoproterenol infusion at 40 μg/kg/h reduced the d. of both β1- and β2ARs by 36% and 43% resp., in left ventricular membranes. Following 6-day infusion of T-0509 at doses sufficient to induce a pos. inotropic effect (5-40 μg/kg/h), the ED50 value of T-0509 (i.v.) for LVdP/dtmax was also increased up to fourfold. In contrast to isoproterenol, infusion of T-0509 caused selective down-regulation of β1ARs by 30% without changing the number of β2ARs. These results indicate that long-term application of a selective β1AR full agonist causes desensitization to its inotropy in vivo, with subtype-selective down-regulation of β1ARs in cardiac ventricles.

IT 96843-99-1, T-0509
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(desensitization and selective down-regulation of rat cardiac β1-adrenoceptors by prolonged in vivo infusion of T-0509, a β1-adrenoceptor full agonist)
RN 96843-99-1 HCAPLUS
CN 1,2-Benzenediol, 4-[(1R)-2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1-hydroxyethyl]- (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 50 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:3546 HCAPLUS
DOCUMENT NUMBER: 124:111248
ORIGINAL REFERENCE NO.: 124:20627a,20630a
TITLE: Arbutamine stress thallium-201 single-photon emission computed tomography using a computerized closed-loop delivery system Multicenter trial for evaluation of safety and diagnostic accuracy
AUTHOR(S): Kiat, Hosen; Iskandrian, Abdulmassih S.; Villegas, Bernard J.; Starling, Mark R.; Berman, Daniel S.
CORPORATE SOURCE: Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA
SOURCE: Journal of the American College of Cardiology (1995), 26(5), 1159-67
CODEN: JACCDI; ISSN: 0735-1097
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB This study sought to evaluate the efficacy and safety of arbutamine when used in conjunction with thallium-201 single-photon emission computed tomog. (SPECT) in a multicenter trial and to compare arbutamine stress and treadmill exercise thallium-201 SPECT for diagnostic sensitivity and myocardial perfusion pattern. Arbutamine is a potent beta-agonist developed specifically for pharmacol. stress testing. Arbutamine was administered by a novel computerized closed-loop device that measures heart rate and adjusts arbutamine infusion to achieve a selected rate of heart rate increase toward a predetd. limit. The cohort included 184 patients who underwent arbutamine stress testing, of whom 122 (catheterization group) had angiog. defined coronary artery disease (≥50% diameter stenosis of a major coronary artery), and 62 had a low pretest likelihood of coronary artery disease (low likelihood group). A

subset of 69 patients from the catheterization group underwent both arbutamine and exercise stress testing. Hemodynamic responses during arbutamine and exercise stress testing demonstrated no significant difference in percent increase in heart rate (81% vs. 76%) or systolic blood pressure (26% vs. 30%). The sensitivity for detecting coronary artery disease (≥50% stenosis) using arbutamine thallium-201 SPECT was 87% (95% for detecting ≥70% stenoses), and the normalcy rate in the low likelihood group was 90%. In patients completing both arbutamine and exercise stress testing, thallium-201 SPECT sensitivity for detecting coronary artery disease (≥50% stenosis) was 94% and 97% (p = NS), resp. Furthermore, SPECT segmental visual score agreement (defect vs. no defect) showed a concordance of 92% between arbutamine and exercise results (kappa 0.80, p < 0.001). The stress thallium-201 SPECT segmental scores showed 83% exact agreement (kappa 0.69, p < 0.001), and anal. of the reversibility of segments with stress perfusion defects demonstrated 86% exact agreement (kappa 0.68, p < 0.001). In general, side effects associated with arbutamine were well tolerated and resolved with discontinuation of infusion. Arbutamine, administered by a closed-loop feed-back system was shown to be a safe and effective pharmacol. stress agent. Arbutamine stress thallium-201 SPECT appears to be accurate for the diagnosis of coronary artery disease with a diagnostic efficacy similar to that of treadmill exercise thallium-201 studies.

IT 128470-16-6, Arbutamine
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arbutamine stress thallium-201 SPECT for evaluation of safety and diagnostic accuracy in coronary artery disease)

RN 128470-16-6 HCAPLUS

CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 51 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:999090 HCAPLUS

DOCUMENT NUMBER: 124:76188

ORIGINAL REFERENCE NO.: 124:13945a,13948a

TITLE: Pharmacological effects of concomitant administration of β-adrenoceptor blocker and agonist in normal subjects: characterization by heart rate response to exercise. Effects of β-blocker combined with β-agonist

AUTHOR(S): Karita, M.; Sato, H.; Koretsune, Y.; Imai, K.; Ozaki,

H.; Yokoyama, H.; Hori, M.; Takeda, H.; Inoue, M.; Kamada, T.
CORPORATE SOURCE: School of Medicine, Osaka University, Suita, 565, Japan
SOURCE: European Journal of Clinical Pharmacology (1995), 48(6), 467-71
CODEN: EJCPAS; ISSN: 0031-6970
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The effects of a combination regimen of metoprolol and β1-adrenoceptor agonist denopamine on resting and exercise heart rate were studied in 10 normal volunteers. Maximal ramp upright bicycle exercise was performed three times at 1-wk intervals. Two hours before each exercise test, 5 mg metoprolol plus 20 mg denopamine, 5 mg metoprolol plus a denopamine placebo, or two placebos were orally administered in a double-blind fashion. During exercise after placebo administration, heart rate increased in parallel with the exercise intensity. Compared to the placebo values, resting heart rate was significantly decreased by an average of 10 beats·min-1 by 5 mg metoprolol, whereas it was not altered by the combination regimen. During exercise, however, both the combination regimen and metoprolol alone showed a significant neg. chronotropic effect, decreasing peak exercise heart rate by an average of 14 and 21 beats·min-1, resp. Peak oxygen uptake was also significantly decreased by both regimens. Thus, concomitant administration of 5 mg metoprolol and 20 mg denopamine exerts an effective β-adrenoceptor blocking action during exercise but a minimal effect at rest in normal subjects. The combination regimen appears to have a favorable pharmacol. profile for β-adrenoceptor blocker therapy in patients with chronic heart failure.
IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(concomitant administration of β-adrenoceptor blocker and agonist effect on heart rate response to exercise in normal humans)
RN 71771-90-9 HCAPLUS
CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 52 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:998182 HCAPLUS

DOCUMENT NUMBER: 124:176115
ORIGINAL REFERENCE NO.: 124:32663a,32666a
TITLE: Preparation of substituted arylsulfonamides as selective β3 agonists for the treatment of diabetes and obesity.
INVENTOR(S): Fisher, Michael H.; Naylor, Elisabeth M.; Ok, Dong; Weber, Ann E.; Shih, Thomas; Ok, Hyun
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9529159	A1	19951102	WO 1995-US4956	19950421 <--
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5541197	A	19960730	US 1995-404566	19950321 <--
AU 9523937	A	19951116	AU 1995-23937	19950421 <--
AU 687558	B2	19980226		
EP 757674	A1	19970212	EP 1995-917116	19950421 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09512275	T	19971209	JP 1995-527797	19950421 <--
JP 3149186	B2	20010326		
FI 9604314	A	19961025	FI 1996-4314	19961025 <--
NO 9604548	A	19961223	NO 1996-4548	19961025 <--

PRIORITY APPLN. INFO.:

US 1994-233166	A	19940426
US 1995-404565	A	19950321
US 1995-404566	A	19950321
WO 1995-US4956	W	19950421

OTHER SOURCE(S): MARPAT 124:176115
GI



I



II

AB Title compds. [I; m = 0, 1; n = 0-5; r = 0-3; A = heterocyclyl, benzoheterocyclyl, heterocycloheterocyclyl, Ph, benzocycloalkyl; R1 = OH, O, halo, cyano, amino, CF3, sulfonylamino, (substituted) alkyl, etc.; R2, R3 = H, (substituted) alkyl; R4, R5 = H, alkyl, halo, amino, sulfonylamino, OH, etc; R6 = H, alkyl; R7 = Z(R11)n; R11 = R1, provided that when A = Ph, R11 ≠ alkyl; X = CH2, CH2CH2, CH:CH, CH2O; Z = Ph, naphthyl, heterocyclyl, heterocycloheterocyclyl] were prepared as selective β3 adrenergic receptor agonists with very little β1 and β2 adrenergic receptor activity which are capable of increasing lipolysis and energy expenditure in cells (no data). The compds. thus have potent activity in the treatment of Type II diabetes and obesity. The compds. can also be used to lower triglyceride levels and cholesterol levels or raise high d. lipoprotein levels or to decrease gut motility. In addition, the compds. can be used to reduce neurogenic inflammation or as antidepressant agents. Title compound (II) was prepared in several steps.

IT 173900-52-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity)

RN 173900-52-2 HCAPLUS

CN Benzenesulfonamide, N-[4-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]phenyl]-4-iodo- (CA INDEX NAME)



L10 ANSWER 53 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:938107 HCAPLUS
DOCUMENT NUMBER: 124:8408
ORIGINAL REFERENCE NO.: 124:1780h,1781a
TITLE: Preparation of hydroxyaminoethylphenylsulfonamide catecholamine surrogates useful as β3 adrenergic agonists.
INVENTOR(S): Washburn, William N.; Girotra, Ravindar N.; Sher, Philip M.; Mikkilineni, Amarendra B.; Poss, Kathleen M.; Mathur, Arvind; Gavai, Ashvinikumar; Bisacchi, Gregory S.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: Eur. Pat. Appl., 147 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 659737	A2	19950628	EP 1994-120281	19941221 <--
EP 659737	A3	19970305		
EP 659737	B1	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
TW 424082	B	20010301	TW 1994-83111890	19941219 <--
HU 72302	A2	19960429	HU 1994-3694	19941220 <--
HU 220063	B	20011028		
CA 2138675	A1	19950622	CA 1994-2138675	19941221 <--
CA 2138675	C	20070501		
FI 9406003	A	19950622	FI 1994-6003	19941221 <--
NO 9404969	A	19950622	NO 1994-4969	19941221 <--
AU 9481635	A	19950629	AU 1994-81635	19941221 <--
AU 688417	B2	19980312		
JP 07206806	A	19950808	JP 1994-336251	19941221 <--
CN 1109050	A	19950927	CN 1994-113297	19941221 <--
ZA 9410213	A	19960621	ZA 1994-10213	19941221 <--
AT 235463	T	20030415	AT 1994-120281	19941221
ES 2194857	T3	20031201	ES 1994-120281	19941221

PRIORITY APPLN. INFO.: US 1993-171285 A 19931221
OTHER SOURCE(S): CASREACT 124:8408; MARPAT 124:8408
GI



I



II

AB Title compds. [I; A = bond, (CH2)n, CHB; n = 1-3; B = cyano, CONR9R91, CO2R7; R1 = alkyl, aryl, aralkyl; R2 = H, OH, alkoxy, CH2OH, cyano, CO2R7, CO2H, CONH2, tetrazolyl, CH2NH2, halo; R3 = H, alkyl, heterocyclyl, (substituted) Ph; R4 = H, alkyl, B; R5, R51 = H, alkoxy, alkyl, halo, OH, cyano, (CH2)nNR6COR7, CONR6R61, CONR6OR6, CO2R6, SR7, SOR7, SO2R7, NR6SO2R1, NR6R61, NR6COR7, OCH2CONR6R61, OCH2CO2R7, aryl; R5R51 = atoms to form aryl, heterocyclyl; R6, R61 = H, alkyl; R7 = alkyl; R9, R91 = H, alkyl, cycloalkyl, aralkyl, aryl, heteroaryl; R9R91N = heterocyclyl; with the proviso that when A = bond or (CH2)n and R3 = H or unsubstituted alkyl, then R4 = B or substituted alkyl], were prepared for treating diabetes, obesity, intestinal hypermotility, etc. (no data). Thus, 3,4-dimethoxybenzaldehyde in THF was treated with PhCH2MgCl in THF followed by 20 min reflux to give 90% α-(3,4-dimethoxyphenyl)benzeneethanol; Jones oxidation gave 89% 1-(3,4-dimethoxyphenyl)-2-phenylethanone. The latter was heated at 160° with NH4O2CH to give N-[1-(3,4-dimethoxyphenyl)-2-phenylethyl]formamide, which was treated with HCl in MeOH to give 77% α-(3,4-dimethoxyphenyl)benzeneethanamine hydrochloride. This was converted to the free base, which in MeCN was treated with 2-bromo-1-[4-phenylmethoxy-3-methylsulfonylamino]phenylethanone (preparation given) and then NaBH4 in EtOH to give title compound (II), isolated as the trifluoroacetate salt.

IT 170685-93-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of catecholamine surrogates useful as β3 adrenergic agonists)

RN 170685-93-5 HCAPLUS

CN Benzoic acid, 4-[[[5-[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]amino]sulfonyl]-, methyl ester (CA INDEX NAME)



L10 ANSWER 54 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:852256 HCAPLUS
DOCUMENT NUMBER: 123:246371
ORIGINAL REFERENCE NO.: 123:43731a,43734a
TITLE: Circulatory, hormonal, and metabolic effects of arbutamine compared to exercise in persons with known or suspected coronary artery disease
AUTHOR(S): Dorn, Karen Lavonne Toft
CORPORATE SOURCE: Virginia Polytechnic Institute and State Univ., Blacksburg, VA, USA
SOURCE: (1994) 191 pp. Avail.: Univ. Microfilms Int., Order No. DA9524776
From: Diss. Abstr. Int., B 1995, 56(3), 1342
DOCUMENT TYPE: Dissertation
LANGUAGE: English
AB Unavailable
IT 128470-16-6, Arbutamine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(circulatory, hormonal, and metabolic effects of arbutamine compared to exercise in persons with known or suspected coronary artery disease)
RN 128470-16-6 HCAPLUS
CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 55 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:800566 HCAPLUS
DOCUMENT NUMBER: 123:218091
ORIGINAL REFERENCE NO.: 123:38519a,38522a
TITLE: Protective effects of denopamine on the abnormal hemodynamics induced by ·OH in anesthetized

rats
AUTHOR(S): Huang, Xienan; Wu, Lunkuan; Liu, Guoxiong; Wu, Qin
CORPORATE SOURCE: Dept. Pharmacology, Zunyi Med. Coll., Zunyi, 563003, Peop. Rep. China
SOURCE: Zhongguo Yaolixue Tongbao (1994), 10(6), 460-3
CODEN: ZYTOE8; ISSN: 1001-1978
PUBLISHER: Anhui Yike Daxue Linchuan Yaoli Yanjiuso
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB The effects of denopamine (Deno) on the abnormal hemodynamics induced by exogenous hydroxyl free radical (·OH) were investigated in anesthetized rats. I.v. administration of ·OH-generating solution (H2O2 1 mmol·L-1 with equimolar CuCl2 and vitamin C) 5 mL·kg-1 significantly decreased heart LVSP, LVSP + R, MAP, +dP/dtmax and -dP/dtmax, and increased LVEDP in anesthetized rats. These effects continued in the whole surveying period (1h). Preadministration (i.v.5 min before ·OH) of Deno 180 'g·K-1 followed by i.v. infusion of 30 μg·kg-1·min-1 after administration of ·OH significantly improved these abnormal hemodynamic indexes induced by ·OH except LVSP. The improvement of LVEDP was specifically significant. Furthermore, the heightened serum malondialdehyde (MAD) content induced by ·OH was also decreased by Deno. The clin. significance of the results is discussed.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(protective effects of denopamine on the abnormal hemodynamics induced by ·OH in anesthetized rats)
RN 71771-90-9 HCAPLUS
CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 56 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:229455 HCAPLUS
DOCUMENT NUMBER: 122:49084
ORIGINAL REFERENCE NO.: 122:9345a,9348a
TITLE: Preparation of sulfonamides as fungicides.
INVENTOR(S): Bartroli, Javier; Anguita, Manuel; Belloc, Jordi; Carceller, Elena; Almansa, Carmen
PATENT ASSIGNEE(S): J. Uriach and Cia.S.A., Spain

SOURCE: U.S., 18 pp. Cont.-in-part of U.S. Ser. No. 772,838, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5360813	A	19941101	US 1992-945589	19920916 <--
ES 2024332	A6	19920216	ES 1990-2712	19901008 <--
US 5344839	A	19940906	US 1993-2898	19930111 <--

PRIORITY APPLN. INFO.: ES 1990-2712 A 19901008
US 1991-772838 B2 19911008
US 1992-945589 A3 19920916
OTHER SOURCE(S): MARPAT 122:49084
GI



I

AB The sulfonamides I [R1= (halo)alkyl, aryl, etc.; R2= R1,H; R1R2= ring; R3=H;R2OR3=(un)substituted oxazolidinyl; R4=H, alkyl; X= CH or N; Ar=(un)substituted Ph] are prepared as agrochem. and medical fungicides (no data). 2-(2,4-Difluorophenyl)-3-amino-1-(1H-1,2,4-triazol-1-yl)propan-2-ol was reacted with methanesulfonyl chloride, in Et3N-containing Cl2CH2, to give 2-(2,4-difluorophenyl)-3-(methanesulfonamido)-1-(1H-1,2,4-triazol-1-yl)propan-2-ol.

IT 159895-91-7P
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides as fungicides)

RN 159895-91-7 HCAPLUS

CN Methanesulfonamide, N-[2-(2,4-dichlorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl]-N-(2-phenylethyl)- (CA INDEX NAME)



L10 ANSWER 57 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:645660 HCAPLUS
DOCUMENT NUMBER: 121:245660
ORIGINAL REFERENCE NO.: 121:44579a,44582a
TITLE: Vascular smooth muscle relaxation of denopamine in isolated pig pulmonary artery
AUTHOR(S): Aikawa, Jo; Fukazawa, Masayuki; Ishikawa, Michirou; Moroi, Masao; Namiki, Atsushi; Tamaguchi, Tetsu
CORPORATE SOURCE: Third Dep. Internal Med., Ohashi Hosp., Japan
SOURCE: Yakuri to Chiryo (1973-2000) (1994), 22(3), 1447-52
CODEN: YACHDS; ISSN: 0386-3603
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB The authors investigated the mechanism of vascular relaxation by denopamine, which has been reported as a selective β1-agonist, in isolated pig pulmonary artery. Denopamine relaxed dose-dependently (10-7.apprx.10-5 M) the ring segments which were partially precontracted with 10-6 M norepinephrine, but did not relax those precontracted with 40 mM K+. The relaxation was not significantly inhibited by pretreatment with 10-5 M metoprolol. Denopamine produced parallel shifts in concentration-response curves to phenylephrine. The Schild plot anal. resulted in a linear regression of a slope of 1.097, which was not significantly different from unity, and the pA2 value of denopamine against phenylephrine was 5.59. In conclusion, vascular smooth muscle relaxation by denopamine in isolated pig pulmonary artery was mediated the blocking effect of α1-adrenoceptors. These findings suggest that denopamine may be effective in the treatment of congestive heart failure with pulmonary hypertension.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vasodilating activity of denopamine in isolated pig pulmonary artery as α1-adrenoceptor blocker)
RN 71771-90-9 HCAPLUS
CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 58 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:595402 HCAPLUS
DOCUMENT NUMBER: 121:195402
ORIGINAL REFERENCE NO.: 121:35219a,35222a
TITLE: The effect of denopamine on the ventricular contractility in experimental hypoxia
AUTHOR(S): Hideaki, Kakura; Kenhichi, Miyahara; Jun-ichi, Sanada; Terukatsu, Arima; Hiroshi, Sakamoto
CORPORATE SOURCE: Faculty Medicine, Kagoshima University, Japan
SOURCE: Kokyu to Junkan (1994), 42(6), 585-91
CODEN: KOJUA9; ISSN: 0452-3458
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB The effect of denopamine(DNOP) on both cardiac contractility and cardiac metabolism were investigated and compared with the effects of isoproterenol (ISP) in a canine heart model with low cardiac function induced by exptl. hypoxia. ISP significantly increased the cardiac contractility in normoxia, but it did not do so in hypoxia. In contrast, DNOP augmented contractile force of the left ventricle in normoxia as well as in hypoxia. Although no significant difference of lactic acid production was found between DNOP and ISP in normoxia, the production of lactic acid by DNOP was significantly less than that by ISP in hypoxia. From these results, it is suggested that DNOP can be expected to improve the cardiac function in patients with pump failure due to hypoxia resulting from acute or chronic respiratory failure.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of denopamine on ventricular contractility in exptl. hypoxia)
RN 71771-90-9 HCAPLUS
CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 59 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:570141 HCAPLUS
DOCUMENT NUMBER: 121:170141
ORIGINAL REFERENCE NO.: 121:30618h,30619a
TITLE: Effects of dobutamine and arbutamine on regional myocardial function in a porcine model of myocardial ischemia
AUTHOR(S): Hammond, H. Kirk; McKirnan, M. Dan
CORPORATE SOURCE: Vet. Aff. Med. Cent., La Jolla, CA, 3350, USA
SOURCE: Journal of the American College of Cardiology (1994), 23(2), 475-82
CODEN: JACCDI; ISSN: 0735-1097
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The present study was performed to determine the mechanisms for catecholamine-induced wall motion abnormalities and to compare the diagnostic efficacy of 2 catecholamines: arbutamine and dobutamine. Catecholamine stress echocardiog. is used to induce regional wall motion abnormalities for the detection of coronary artery disease, but the mechanism by which these abnormalities occur is unknown. Pigs were instrumented with left circumflex coronary artery ameroid constrictors, sonomicrometers to measure transmural wall thickening in the left circumflex (ischemic) and left anterior descending (control) coronary artery beds and a pressure gauge to measure left ventricular pressure and its 1st derivative (dP/dt). Myocardial blood flow was measured by microspheres. At 38 days after surgery, percent wall thickening was normal at rest in both beds but abnormal in the left circumflex coronary artery bed during atrial pacing. These findings were associated with reduced myocardial blood flow in the ischemic bed during atrial pacing. Dobutamine infusion increased percent wall thickening, with no differences between the 2 beds. In contrast, arbutamine infusion increased percent wall thickening only in the nonischemic bed, with no effect on percent wall thickening in the ischemic bed. Although the endocardial/epicardial blood flow ratio tended to be reduced in the left circumflex artery bed during catecholamine infusion, both agents were similar in this effect. Despite differences in function between the beds, there was no difference in transmural myocardial blood flow between the 2 beds during catecholamine infusion. At matched metabolic demands, arbutamine elicited greater differences in percent wall thickening between the 2 beds than did dobutamine. Arbutamine was able to provoke regional differences in function in a manner superior to dobutamine. This occurred independently of altered transmural myocardial blood flow or differences in hemodynamic effects between the agents. Differences in their inotropic properties may be important in explaining their different effects on the ischemic

myocardium.
IT 128470-16-6, Arbutamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dobutamine and arbutamine effects on regional myocardial function in heart ischemia)
RN 128470-16-6 HCAPLUS
CN 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 60 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1992:489877 HCAPLUS
DOCUMENT NUMBER: 117:89877
ORIGINAL REFERENCE NO.: 117:15681a,15684a
TITLE: Preparation of N-alkyl-1-[1-(benzylthio)cyclopropyl]-1-phenylethanolamines and analogs as medical fungicides
INVENTOR(S): Haenel, Heinz; Kirsch, Reinhard; Kottmann, Hariolf
PATENT ASSIGNEE(S): Hoechst A.-G., Germany
SOURCE: Eur. Pat. Appl., 53 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 488169	A1	19920603	EP 1991-120186	19911126 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FI 9105566	A	19920529	FI 1991-5566	19911126 <--
CA 2056311	A1	19920529	CA 1991-2056311	19911127 <--
NO 9104654	A	19920529	NO 1991-4654	19911127 <--
AU 9188140	A	19920604	AU 1991-88140	19911127 <--
AU 642553	B2	19931021		
ZA 9109356	A	19920826	ZA 1991-9356	19911127 <--
JP 04290853	A	19921015	JP 1991-335822	19911127 <--
HU 62265	A2	19930428	HU 1991-3710	19911128 <--
PRIORITY APPLN. INFO.:			DE 1990-4037819 A	19901128
OTHER SOURCE(S):	MARPAT 117:89877			

AB R4R5NCH2CR1R2ZXR3 [R1 = CMe3, (substituted)phenyl, -biphenylyl, -tetrahydronaphthyl, -heterocyclyl, etc.; R2 = OH, F, Cl, Br, alkanoyloxy, alkoxy, etc.; R3 = (substituted)(cyclo)alkyl, -alkenyl, -Ph, -biphenylyl, -heteroaryl, etc.; R4 = H, alkyl, alkenyl, PhCH2, etc.; R5 = H, (cyclo)alkenyl, Ph, thienyl, etc.; X = O, SO0-2; Z = 1,1-cyclopropylidene (throughout)] were prepared Thus, 4-ClC6H4COZSCH2C6H4-4 was treated with Me3S(O)I and the product condensed with BuNH2 to give BuNHCH2CR1(OH)ZSCH2C6H4-4 (R1 = 4-ClC6H4) which gave 57% increase of survival time of Candida albicans-infected mice receiving 14 + 50 mg/kg-day orally with 9 + 50 mg/kg-day fluconazole orally over mice receiving fluconazole only.

IT 142671-98-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as medical fungicide)

RN 142671-98-5 HCAPLUS

CN Benzenemethanol, 4-chloro-α-[1-[[(4-chlorophenyl)methyl]thio]cyclopropyl]-α-[[[2-(4-methoxyphenyl)ethyl]amino]methyl]- (CA INDEX NAME)



L10 ANSWER 61 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1988:454475 HCAPLUS

DOCUMENT NUMBER: 109:54475

ORIGINAL REFERENCE NO.: 109:9175a,9178a

TITLE: Preparation of α-(aminoalkyl)-4-hydroxy-3-(alkylthio)benzenemethanols as antihypertensives

INVENTOR(S): Philion, Richard E.

PATENT ASSIGNEE(S): Sterling Drug Inc., USA

SOURCE: U.S., 21 pp. Cont.-in-part of U.S. Ser. No. 937,926, abandoned.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 4695589	A	19870922	US 1983-499102	19830527	<--
BE 856055	A1	19771223	BE 1977-8219	19770623	<--
ZA 7703762	A	19780530	ZA 1977-3762	19770623	<--
AT 7806347	A	19800115	AT 1978-6347	19780901	<--
AT 358009	B	19800811			
AT 7806348	A	19800215	AT 1978-6348	19780901	<--
AT 358558	B	19800925			
CA 1091246	A2	19801209	CA 1980-347766	19800317	<--
CA 1092142	A2	19801223	CA 1980-347767	19800317	<--
DK 8003937	A	19800917	DK 1980-3937	19800917	<--
DK 8003938	A	19800917	DK 1980-3938	19800917	<--
CH 630068	A5	19820528	CH 1981-445	19810122	<--
DK 8300764	A	19830222	DK 1983-764	19830222	<--
FI 8300796	A	19830309	FI 1983-796	19830309	<--
FI 8300797	A	19830309	FI 1983-797	19830309	<--
PRIORITY APPLN. INFO.:			US 1976-699856	A2 19760625	
			US 1977-803372	A2 19770603	
			US 1978-937926	A2 19780830	
			FI 1977-1976	A 19770623	
			AT 1977-4493	A 19770624	
			CA 1977-281375	A3 19770624	
			CH 1977-7791	A 19770624	
			DK 1977-2817	A 19770624	

OTHER SOURCE(S): CASREACT 109:54475; MARPAT 109:54475

GI



I

AB Title compds. I (R1 = H, alkanoyl; R2, R3 = H, alkyl; Ar = alkoxyphenyl; n = 1, 2) and their acid addition salts are prepared as antihypertensives. Sodium borohydride reduction of 9.0 g 4'-hydroxy-2-[3-(4-methoxyphenyl)-1-methylpropyl]amino-3'-(methylthio)acetophenone 4'-acetate hydrochloride in MeOH gave 7.2 g I (R1 = H, R2 = H, R3 = Me, Ar = 4-MeOC6H4, n = 2) acetate which at 15 mg/kg p.o. in rats lowered blood pressure by 40 mm.

IT 70875-83-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antihypertensive)

RN 70875-83-1 HCAPLUS

CN Benzenemethanol, 4-hydroxy-α-[[[3-(4-methoxyphenyl)propyl]amino]methyl]-3-(methylthio)-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 70875-82-0

CMF C19 H25 N O3 S



CM 2

CRN 64-19-7
CMF C2 H4 O2

L10 ANSWER 62 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1987:12620 HCAPLUS
DOCUMENT NUMBER: 106:12620
ORIGINAL REFERENCE NO.: 106:2069a,2072a
TITLE: General pharmacological study of denopamine (3). Effects on gastrointestinal system and others
AUTHOR(S): Takaiti, Osasi; Ikeo, Tomihiro; Ishizuka, Tohru; Ikezawa, Katsuo; Takido, Mine; Satachi, Harumi
CORPORATE SOURCE: Biol. Res. Lab., Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Yakuri to Chiryo (1973-2000) (1985), 13(11), 6367-87
CODEN: YACHDS; ISSN: 0386-3603
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



AB Denopamine (I) [71771-90-9] (i.v. or oral) decreased intestinal motility but had no effect on stress-induced gastric ulceration when administered s.c. to mice. In rats, I administered intraduodenally slightly decreased pepsin secretion, had no effect on acid output, and slightly stimulated biliary secretion. I inhibited spontaneously contracted rabbit jejunum preparation, and noncompetitively inhibited nicotine-, methacholine-,

histamine-, or BaCl2-induced guinea pig ileum contractions. I at ≥1 μM stimulated amylase secretion in isolated rat parotid gland and induced a weak bronchodilation when administered i.v. to rats. I decreased uterine motility, oxytocin-induced contractions and hindered incomplete tetanic contractions of soleus muscle in rats. I had no influence on induced contractions of nictating membrane in cats. I had no effect on phenylephrine-induced contractions of guinea-pig vas deferens, or the tension of isolated aorta of rabbit. K-depolarized prepns. of guinea-pig teania coli were relaxed by I at 0.28 mM. I had weak anti-inflammatory, antiphlogistic, analgesic, infiltration anesthetic, or local irritant activities. Surface anesthetic and mucous irritant effects were not observed with I. I had no effects on blood coagulation and fibrinolysis in rats, but a weak inhibitory activity against platelet aggregation was observed in rats and dogs. I at 1 mg/kg, i.p., did not alter blood glucose, blood lactate, blood glycerol, and plasma insulin concns. in rats.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 63 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1987:12352 HCAPLUS
DOCUMENT NUMBER: 106:12352
ORIGINAL REFERENCE NO.: 106:2017a,2020a
TITLE: General pharmacology of the metabolites of denopamine
AUTHOR(S): Narita, Hiroshi; Ikezawa, Katsuo; Inamasu, Masanori; Ishizuka, Tohru; Nishiyama, Shinsuke; Ikeo, Tomihiro; Nagao, Taku
CORPORATE SOURCE: Biol. Res. Lab., Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Yakuri to Chiryo (1973-2000) (1985), 13(11), 6389-403
CODEN: YACHDS; ISSN: 0386-3603
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB General pharmacol. of the metabolites of denopamine, i.e. 4'-demethyldenopamine (M1) [87081-63-8], 3-methyoxydenopamine (M2) [87081-64-9] and 4'-demethyl-3-methoxydenopamine (M3) [87081-59-2], were

studied. LD50 values (i.v.) of the metabolites in mice were 115 mg/kg for M1, 230 mg/kg for M2, and 195 mg/kg for M3. The metabolites did not exhibit central action at 3 mg/kg, i.v. or less. M1 decreased blood pressure and increased heart rate and left ventricular dp/dtmax in anesthetized dogs. M1 also increased contractile force of isolated guinea pig heart at 0.01 μg/heart or more. Effects of the metabolites on respiratory system, renal function, gastrointestinal system, inflammation and metabolic system were negligible or were weaker than the effects on circulatory system. Effects of the metabolites on autonomic nervous system and smooth muscle were similar to or less potent than those of denopamine. β-Adrenergic agonistic properties were observed with M1, however, neither agonistic nor antagonistic properties on the β-adrenoceptor were observed with M2 and M3. From these results and the evidence that these metabolites were not detected in blood after denopamine administration, it is concluded that these metabolites do not contribute to the actions of denopamine.

IT 71771-90-9D, Denopamine, metabolites
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 64 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1987:183 HCAPLUS
DOCUMENT NUMBER:	106:183
ORIGINAL REFERENCE NO.:	106:31a,34a
TITLE:	General pharmacological study of denopamine (1). Effects on the central nervous system
AUTHOR(S):	Tanaka, Takashi; Yamamura, Michio; Matsuoka, Yuzo; Ishida, Ryuichi; Iwasawa, Yoshiro
CORPORATE SOURCE:	Saf. Res. Lab., Tanabe Seiyaku Co., Ltd., Japan
SOURCE:	Yakuri to Chiryo (1973-2000) (1985), 13(11), 6343-53 CODEN: YACHDS; ISSN: 0386-3603
DOCUMENT TYPE:	Journal
LANGUAGE:	Japanese

AB Effects of denopamine [71771-90-9] on the central nervous system were investigated. Mild ptosis and a slight increase in spontaneous locomotion were observed in mice. A decrease in spontaneous motor activity was also

detected after oral administration of 300 mg/kg or more of denopamine. Apomorphine-induced cage-climbing behavior was depressed by 10 mg/kg (i.v.) or 1000 mg/kg (orally). At 3 mg/kg or more, denopamine slightly prevented reserpine-induced hypothermia, without affecting reserpine-induced catalepsy or ptosis. No marked effects of denopamine were noted in vivo at maximal doses (300 or 1000 mg/kg, orally, or 10 mg/kg, i.v.) for the other effects. Denopamine did not affect MAO activity of rat brain mitochondria. The results suggest that denopamine has no systemic side effects on the central nervous system.

IT 71771-90-9, Denopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of, central nervous system response in)

RN 71771-90-9 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-4-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 65 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1984:406799 HCAPLUS

DOCUMENT NUMBER: 101:6799

ORIGINAL REFERENCE NO.: 101:1155a,1158a

TITLE: 2-Aminoethyl ether derivatives, and their pharmaceutical compositions

INVENTOR(S): Cantello, Barrie Christian Charles

PATENT ASSIGNEE(S): Beecham Group PLC, UK

SOURCE: Eur. Pat. Appl., 87 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 99707	A1	19840201	EP 1983-303983	19830708 <--
EP 99707	B1	19861210		
R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
AU 8316826	A	19840223	AU 1983-16826	19830714 <--
AU 557743	B2	19870108		
ZA 8305126	A	19840627	ZA 1983-5126	19830714 <--
US 4629737	A	19861216	US 1983-513869	19830714 <--

CA 1253870	A1	19890509	CA 1983-432465		19830714 <--
JP 59031740	A	19840220	JP 1983-128035		19830715 <--
PRIORITY APPLN. INFO.:			GB 1982-20645	A	19820716
			GB 1982-28753	A	19821007
			GB 1982-35672	A	19821215

OTHER SOURCE(S): MARPAT 101:6799
GI



I

AB Amines I [R = Ph, alkyl-, halo-, or (trifluoromethyl)phenyl, PhOCH2, 2-benzofuryl; R1 = alkyl, phenylalkyl; R2 = H, Me; n = 1, 2; R3 = CO2H, carboxyalkyl, carboxyalkenyl, hydroxyalkyl, hydroxyalkenyl, aminoalkyl, aminoalkenyl, alkoxy, alkylthio, alkylamino, hydroxyalkoxy, hydroxyalkylthio, hydroxyalkylamino, aminoalkoxy, aminoalkylthio, aminoalkylamino, ZZ1CO2H (Z = O, S, NH; Z1 = alkylene, alkenylene)] were prepared, and they exhibited antidiabetic activity. A mixture of 4-(MeCOCH2)C6H4OCH2CO2Me and 3-ClC6H4CH(OMe)CH2NH2 in PhMe was refluxed 2 h, and the mixture was treated with Pt and H2 to give I (R = 3-ClC6H4, R1 = R2 = Me, n = 1, R3 = 4-OCH2CO2Me). Some I also showed antiinflammatory activity and inhibited blood platelet aggregation.

IT 90470-31-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antidiabetic activity of)

RN 90470-31-8 HCAPLUS

CN Acetamide, 2-[4-[2-[[2-(3-chlorophenyl)-2-methoxyethyl]amino]ethyl]phenoxy]-N-methyl- (CA INDEX NAME)



L10 ANSWER 66 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1984:120862 HCAPLUS
DOCUMENT NUMBER:	100:120862
ORIGINAL REFERENCE NO.:	100:18385a,18388a
TITLE:	Aziridine and phenylethanolamine derivatives
INVENTOR(S):	Alig, Leo; Muller, Marcel
PATENT ASSIGNEE(S):	Hoffmann-La Roche, F., und Co. A.-G., Switz.
SOURCE:	Eur. Pat. Appl., 41 pp. CODEN: EPXXDW
DOCUMENT TYPE:	Patent

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 94595	A1	19831123	EP 1983-104589	19830510	<--
EP 94595	B1	19870114			
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
CA 1219865	A1	19870331	CA 1983-427392	19830504	<--
ZA 8303263	A	19840125	ZA 1983-3263	19830506	<--
IL 68635	A	19861031	IL 1983-68635	19830509	<--
US 4652679	A	19870324	US 1983-492981	19830509	<--
DK 8302093	A	19831115	DK 1983-2093	19830510	<--
FI 8301617	A	19831115	FI 1983-1617	19830510	<--
AU 8314424	A	19831117	AU 1983-14424	19830510	<--
AT 24897	T	19870115	AT 1983-104589	19830510	<--
HU 191523	B	19870330	HU 1983-1627	19830511	<--
NO 8301727	A	19831115	NO 1983-1727	19830513	<--
JP 58206558	A	19831201	JP 1983-82863	19830513	<--
PRIORITY APPLN. INFO.:			CH 1982-3013	A 19820514	
			CH 1983-1434	A 19830316	
			EP 1983-104589	A 19830510	
OTHER SOURCE(S):		MARPAT 100:120862			

GI



AB Aziridines (I) [R = aryl; R1 = 4-R4C6H4 or 5-(R4-substituted)-2-thienyl, R4 = H, lower alkyl or alkanoyl, cyano, etc.; R2, R3 = H, lower alkyl; n = 1-4] were prepared (.apprx.50) and shown to have antidiabetic activity. Thus, 1.70 g (±)-4-[PhCH(OH)CH2NH(CH2)3]C6H4CONH2, 0.8 mL Et3N, 0.6 mL CCl4, 1.65 g Ph3P, and 12 mL MeCN were stirred 2.5 h at 50° to give 1.0 g (±)-aziridine II. Also prepared was, e.g., the thiophene analog (R)-III.

IT 88961-11-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antidiabetic activity of)

RN 88961-11-9 HCAPLUS

CN Benzenesulfonamide, 4-[3-[(2-hydroxy-2-phenylethyl)amino]propyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 67 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1983:438192 HCAPLUS
DOCUMENT NUMBER: 99:38192
ORIGINAL REFERENCE NO.: 99:5993a,5996a
TITLE: α-[(Arylalkyl)amino]alkyl-4-hydroxy-3-(lower alkylsulfinyl)benzenemethanols
INVENTOR(S): Philion, Richard E.
PATENT ASSIGNEE(S): Sterling Drug Inc., USA
SOURCE: U.S., 32 pp. Cont.-in-part of U.S. Ser. No. 803,372, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4374149	A	19830215	US 1978-937928	19780830 <--
IL 52353	A	19810731	IL 1977-52353	19770620 <--
BE 856055	A1	19771223	BE 1977-8219	19770623 <--
FI 7701976	A	19771226	FI 1977-1976	19770623 <--
SE 7707341	A	19780213	SE 1977-7341	19770623 <--
ZA 7703762	A	19780530	ZA 1977-3762	19770623 <--
AU 7726368	A	19790104	AU 1977-26368	19770623 <--
AU 512626	B2	19801023		
DK 7702817	A	19771226	DK 1977-2817	19770624 <--
DK 146386	B	19830926		
DK 146386	C	19840312		
NO 7702245	A	19771228	NO 1977-2245	19770624 <--
NO 144848	B	19810817		
NO 144848	C	19811125		
FR 2366272	A1	19780428	FR 1977-19408	19770624 <--
FR 2366272	B1	19810306		
AT 354420	B	19790110	AT 1977-4493	19770624 <--
AT 7704493	A	19790615		
CA 1091245	A1	19801209	CA 1977-281375	19770624 <--
CH 627447	A5	19820115	CH 1977-7791	19770624 <--
JP 53021134	A	19780227	JP 1977-76034	19770625 <--
NL 7707128	A	19771228	NL 1977-7128	19770627 <--
AT 7806347	A	19800115	AT 1978-6347	19780901 <--
AT 358009	B	19800811		
AT 7806348	A	19800215	AT 1978-6348	19780901 <--
AT 358558	B	19800925		
CA 1091246	A2	19801209	CA 1980-347766	19800317 <--
CA 1092142	A2	19801223	CA 1980-347767	19800317 <--

DK 8003937	A	19800917	DK 1980-3937	19800917	<--
DK 8003938	A	19800917	DK 1980-3938	19800917	<--
CH 630068	A5	19820528	CH 1981-445	19810122	<--
JP 57163358	A	19821007	JP 1982-22953	19820217	<--
JP 57167957	A	19821016	JP 1982-22952	19820217	<--
US 4452816	A	19840605	US 1982-402793	19820728	<--
US 4751246	A	19880614	US 1982-402732	19820728	<--
DK 8300764	A	19830222	DK 1983-764	19830222	<--
FI 8300796	A	19830309	FI 1983-796	19830309	<--
FI 8300797	A	19830309	FI 1983-797	19830309	<--

PRIORITY APPLN. INFO.:

US 1976-699856	A2	19760625
US 1977-803372	A2	19770603
FI 1977-1976	A	19770623
AT 1977-4493	A	19770624
CA 1977-281375	A3	19770624
CH 1977-7791	A	19770624
DK 1977-2817	A	19770624
US 1978-937928	A3	19780830

OTHER SOURCE(S): CASREACT 99:38192; MARPAT 99:38192

AB 4,3-RO(R1SO)C6H3CH(OH)CHR2NHCR3R4(CH2)nR5 [R = H, alkyl, alkanoyl, aroyl, PhSO2, MeC6H4SO2; R1 = alkyl; R2, R3, R4 = H, alkyl; R5 = (un)substituted Ph; n = 1-3] were prepared Thus R6NH2 (R6 = 4-MeOC6H4CH2CH2CHMe) was treated with 4,3-AcO(MeS)C6H3COCH2Br to give 4,3-Ac(MeS)C6H3COCH2NHR6, which was reduced with NaBH4 to yield 4,3-HO(MeS)C6H3CH(OH)CH2NHR6 (I). Oxidation of I with MeC(O)OOH formed 4,3-HO(MeSO)C6H3CH(OH)CH2NHR6 (II). II reduced blood pressure in rats by 40 mm average at 3.0 mg/kg orally. II also showed vasodilator, β-sympatholytic, antiarrhythmic, and cardiotonic activity.

IT 66265-89-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antihypertensive activity of)

RN 66265-89-2 HCAPLUS

CN Benzenemethanol, 4-hydroxy-3-(methylsulfinyl)-α-[[[2-(3,4,5-trimethoxyphenyl)ethyl]amino]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L10 ANSWER 68 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1983:121336 HCAPLUS

DOCUMENT NUMBER: 98:121336
ORIGINAL REFERENCE NO.: 98:18417a,18420a
TITLE: Structure-activity relationships among DDT derivatives
AUTHOR(S): Coats, Joel R.
CORPORATE SOURCE: Dep. Entomol., Iowa State Univ., Ames, IA, 50011, USA
SOURCE: Journal of Environmental Science and Health, Part B: Pesticides, Food Contaminants, and Agricultural Wastes (1983), B18(1), 173-88
CODEN: JPFCD2; ISSN: 0360-1234
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Both steric and electronic factors were shown to be important to the insecticidal activity of DDT-type compds. Some factors are critical to fit or affinity at the site of action, whereas some affect degradation and penetration processes.

IT 83986-73-6
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(insecticidal activity of, structure in relation to)

RN 83986-73-6 HCAPLUS
CN Benzenemethanol, 4-amino-3-fluoro-α-[[[3-(4-methoxyphenyl)propyl]methylamino]methyl]- (CA INDEX NAME)



L10 ANSWER 69 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1983:71655 HCAPLUS
DOCUMENT NUMBER: 98:71655
ORIGINAL REFERENCE NO.: 98:10955a,10958a
TITLE: Secondary amines and pharmaceutical compositions containing them
INVENTOR(S): Smith, David Glynn
PATENT ASSIGNEE(S): Beecham Group PLC, UK
SOURCE: Eur. Pat. Appl., 40 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 63004	A1	19821020	EP 1982-301714	19820401 <--
R: BE, CH, DE, FR, GB, IT, NL, SE				
AU 8282423	A	19821014	AU 1982-82423	19820407 <--
ZA 8202388	A	19830223	ZA 1982-2388	19820407 <--

ES 511336	A1	19831001	ES 1982-511336		19820408 <--
JP 57179140	A	19821104	JP 1982-59483		19820409 <--
ES 519295	A1	19840301	ES 1983-519295		19830126 <--
PRIORITY APPLN. INFO.:			GB 1981-11252	A	19810409
OTHER SOURCE(S):	MARPAT 98:71655				

GI



I

AB Reductive N-alkylation of phenethylamines by phenylacetones gave amines I [R = H, halo, CF3, alkyl; R1 = H, halo; R2 = H, Me; R3 = H, Me; n = 1, 2; Z = alkylene; R4 = alkoxy, OH, (un)substituted amino]. Thus, heating I (R = 3-CF3, R1 = R2 = H, R3 = Me, n = 1, Z = CH2CH2, R4 = OMe), prepared from I (Z = CH:CH), with MeNH2 gave I (R = 3-CF3, R1 = R2 = H, R3 = Me, n = 1, Z = CH2CH2, R4 = NHMe), which was administered to obese mice to give 17.47 g lipids/mouse, in comparison to 21.68 for the control.

IT 84542-07-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antidiabetic activity of)

RN 84542-07-4 HCAPLUS

CN Benzenepropanoic acid, 4-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-β-methyl-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



L10 ANSWER 70 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1983:53384 HCAPLUS
DOCUMENT NUMBER:	98:53384
ORIGINAL REFERENCE NO.:	98:8193a,8196a
TITLE:	Phenethylamine derivatives
PATENT ASSIGNEE(S):	Beecham Group PLC, UK
SOURCE:	Jpn. Kokai Tokkyo Koho, 20 pp. CODEN: JKXXAF
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 57158741	A	19820930	JP 1982-35032	19820305 <--
EP 66351	A1	19821208	EP 1982-301019	19820301 <--
EP 66351	B1	19850626		
R: BE, CH, DE, FR, GB, IT, NL, SE				
ZA 8201436	A	19830223	ZA 1982-1436	19820304 <--
AU 8281166	A	19820909	AU 1982-81166	19820305 <--

PRIORITY APPLN. INFO.: GB 1981-7050 A 19810306
GB 1981-21443 A 19810711

OTHER SOURCE(S): MARPAT 98:53384
GI



I

AB The title compound (I, R, R1 = H, Me; R2 = H, alkyl, cycloalkyl, etc.; R3 = H, halo, OH, alkyl, alkoxy: n = 1, 2) were prepared Thus, a mixture of 2.65 g MeCOCH2C6H4OCH2Ph-p, 2.05 g m-CF3C6H4CH(OH)CH2NH2, and 100 mL toluene was refluxed for 2 h and the product treated with NaBH4 at 10° for 30 min and then at room temperature for 1 h to give 2.5 g a 1:1 diastereomeric mixture of I (R = R3 = H, R1 = Me, R2 = PhCH2). Data for the antidiabetic, antiinflammatory, and blood platelet aggregation-inhibiting activities of I are given.

IT 84023-26-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and pharmacol. activities of)

RN 84023-26-7 HCAPLUS

CN Benzenemethanol, α-[[[2-(4-methoxyphenyl)ethyl]amino]methyl]-3-(trifluoromethyl)- (CA INDEX NAME)



L10 ANSWER 71 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1982:581944 HCAPLUS
DOCUMENT NUMBER: 97:181944
ORIGINAL REFERENCE NO.: 97:30425a,30428a

10521294

TITLE: Alkanolamines
INVENTOR(S): Bercher, Horst; Grisk, Adolf
PATENT ASSIGNEE(S): Akademie der Wissenschaften der DDR, Zentralinstitut fuer Molekularbiologie und Medizin, Ger. Dem. Rep.
SOURCE: Ger. (East), 21 pp.
CODEN: GEXXA8
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 153682	A1	19820127	DD 1978-208533	19781019 <--
PRIORITY APPLN. INFO.:			DD 1978-208533	A1 19781019

OTHER SOURCE(S): CASREACT 97:181944
GI



I

AB Alkanolamines I (R = halo; R1 = H, halo, NH2, acylamino, R3OCONH or R3NHCONH, where R3 = Ph, alkyl or aralkyl; R2 = H when R1 = halo, or halo when R1 ≠ halo; n = 0 or 1), which showed β-sympatholytic activities comparable to propanolol and with greater specificity for blocking β1-receptors of the heart and β2-receptors of peripheral blood vessels and bronchial musculature, were prepared by several known procedures. Thus, 2,5-F2C6H3CH(OH)CH2Cl refluxed 8 h with 3,4-(MeO)2C6H3CH2CH2NH2 in Me2CHOH gave 59% I (R = 2-F, R1 = H, R2 = 5-F, n = 0).

IT 83335-58-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and sympatholytic activity of)

RN 83335-58-4 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-2,5-difluoro- (CA INDEX NAME)

Updated Search

L10 ANSWER 72 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1981:15380 HCAPLUS
DOCUMENT NUMBER: 94:15380
ORIGINAL REFERENCE NO.: 94:2563a,2566a
TITLE: Anticoagulant and hypoglycemic hydroxy[[(trimethoxyphenethyl)amino]methyl]benzyl alcohol
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 55053216	A	19800418	JP 1978-126565	19781013 <--
JP 62031685	B	19870709		

PRIORITY APPLN. INFO.: JP 1978-126565 A 19781013
GI



I

AB Acid addition salts of the 2-(phenethylaminomethyl)benzyl alc. I were prepared and tested for their pharmacol. activities. Thus, 9 g H2NCH2CH2C6H2(OMe)3-2,3,4 was condensed with 10.5 g o-PhCH2OC6H4COCHO in Me2SO to give o-PhCH2OC6H4COCH:NCH2CH2C6H2(OMe)3-2,3,4, which in EtOH was reduced with NaBH4 and the product treated with HCl to give 13.1 g o-PhCH2OC6H4CH(OH)CH2NHCH2CH2C6H2(OMe)3-2,3,4.HCl. Hydrogenation of 5 g the (benzyloxy)benzyl alc. derivative over 1 g 10% Pd/C gave 3.4 g I.HCl, which had anticoagulant and hypoglycemic effects on rats.

IT 69564-78-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and pharmacol. activities of)

RN 69564-78-9 HCAPLUS
CN Benzenemethanol, 2-hydroxy-α-[[[2-(2,3,4-trimethoxyphenyl)ethyl]amino]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L10 ANSWER 73 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1979:121192 HCAPLUS
DOCUMENT NUMBER: 90:121192
ORIGINAL REFERENCE NO.: 90:19175a,19178a
TITLE: Benzyl alcohol derivatives
INVENTOR(S): Ikezaki, Muneyoshi; Otsuka, Hisao; Iwai, Hajime; Inamasu, Masanori; Morita, Takashi
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Fed. Rep. Ger.
SOURCE: Ger. Offen., 13 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
DE 2824291	A1	19781214	DE 1978-2824291	19780602	<--
DE 2824291	C2	19831103			
JP 53149940	A	19781227	JP 1977-65405	19770602	<--
JP 57026583	B	19820605			
GB 1573489	A	19800828	GB 1978-18600	19780510	<--
US 4218479	A	19800819	US 1978-906965	19780518	<--
FR 2392957	A1	19781229	FR 1978-16440	19780601	<--
FR 2392957	B1	19800704			
CH 639638	A5	19831130	CH 1978-6078	19780602	<--

PRIORITY APPLN. INFO.: JP 1977-65405 A 19770602
GI



I

AB Benzyl alc. derivative I (R = H) or its salts were prepared in racemic or l-form

by reduction of the Schiff base formed from o-PhCH2OC6H4COCHO and 2,3,4-(MeO)3C6H2CH2CH2NH2, followed by optional resolution and hydrogenolysis of I (R = PhCH2). In comparison with phenformin, d,l-I (R = H) hydrogen oxalate is .apprx.10 times more effective in reducing blood-sugar levels in the mouse. Thus, oxidation of 2-PhCH2OC6H4COMe with SeO2, followed by Schiff base formation and reduction with NaBH4 gave 66% d,l-I (R = PhCH2), which was hydrogenated over 10% Pd/C to give 85% d,l-I (R = H).

IT 69564-80-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antidiabetic activity of)

RN 69564-80-3 HCAPLUS

CN Benzenemethanol, 2-hydroxy-α-[[[2-(2,3,4-trimethoxyphenyl)ethyl]amino]methyl]-, ethanedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 76454-08-5
CMF C19 H25 N O5



CM 2

CRN 144-62-7
CMF C2 H2 O4

L10 ANSWER 74 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1978:579679 HCAPLUS
DOCUMENT NUMBER:	89:179679
ORIGINAL REFERENCE NO.:	89:27895a,27898a
TITLE:	1-Hydroxyphenyl-2-(3,4-dimethoxyphenethylamino)ethan-1-ols
PATENT ASSIGNEE(S):	Tanabe Seiyaku Co., Ltd., Japan
SOURCE:	Austrian, 5 pp. Division of Austrian 338,242. CODEN: AUXXAK
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AT 343628	B	19780612	AT 1976-5809	19760805 <--
AT 7605809	A	19771015		
AT 338242	B	19770810	AT 1975-7340	19750925 <--
AT 7507340	A	19761215		
PRIORITY APPLN. INFO.:			AT 1975-7340 A	19750925

GI



I

AB Three title ethanolamines I (R = H) and their pharmaceutically acceptable salts, useful as adrenergic β1-receptor stimulators, e.g., increasing heart contraction and pulse, and as antidiabetics, were prepared by hydrogenolysis of the resp. I (R = PhCH2)·HCl over PtO2, Pd/C, Pt, or PdO2 in 80% aqueous Me2CHOH or MeOH. I (R = PhCH2)·HCl were prepared by the addition of PhCH2OC6H4COCH2Cl in CH2Cl2 to 3,4-(MeO)2C6H3CH2CH2NH2 followed by hydrogenolysis. II (R = H, 4-isomer) increased the strength of heart contraction 76% in dogs at 8.0 μg/kg i.v. I (R = H, 2-isomer) decreased blood sugar .apprx.30% in mice at 10 mg/kg orally in mice when given before 1 g-kg glucose s.c.

IT 59121-15-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antidiabetic activity of)

RN 59121-15-2 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-2-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L10 ANSWER 75 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1978:6542 HCAPLUS
DOCUMENT NUMBER: 88:6542
ORIGINAL REFERENCE NO.: 88:1101a,1104a
TITLE: Racemic and optically active 1-hydroxyphenyl-2-(3',4'-dimethoxyphenethyl)amino-1-ethanols
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Austrian, 5 pp.
CODEN: AUXXAK
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AT 338242	B	19770810	AT 1975-7340	19750925 <--
AT 7507340	A	19761215		
AT 343628	B	19780612	AT 1976-5809	19760805 <--
AT 7605809	A	19771015		
PRIORITY APPLN. INFO.:			AT 1975-7340 A	19750925

GI



I, R=H
III, PhCH2



II

AB Racemic aminoethanols I (OH at 2, 3, and 4) were prepared by treating PhCH2OC6H4COCH2Cl in CH2Cl2 with 3,4-(MeO)2C6H3CH2CH2NH2 dropwise at room temperature, reducing the product ketone II with NaBH4, and debenzylating the resultant III with H2 over Pd/C. III (OCH2Ph at 4) was resolved with (-)-D-acetylphenylalanine and the product debenzylated to give (-)-I (OH at 4). I (OH at 3, 4) increased the extent of heart contractions in dogs 55 and 50%, resp., at 10 and 5 μg/kg, resp., without effect on blood pressure. I (OH at 2) decreased blood glucose in mice .apprx.30% at 10 mg/kg s.c., whereas 100 mg/kg phenforurin caused only 13% decrease.

IT 59121-15-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antidiabetic activity of)

RN 59121-15-2 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-2-

hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



L10 ANSWER 76 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1977:534505 HCAPLUS
DOCUMENT NUMBER: 87:134505
ORIGINAL REFERENCE NO.: 87:21361a,21364a
TITLE: Benzyl alcohol derivatives
INVENTOR(S): Ikezaki, Muneyoshi; Okazaki, Yasushi; Ito, Nobuo; Hoshiyama, Masao; Nagao, Taku; Nakajima, Hiromichi
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2656088	A1	19770623	DE 1976-2656088	19761210 <--
DE 2656088	C2	19831006		
JP 52071427	A	19770614	JP 1975-148145	19751211 <--
JP 55032700	B	19800826		
JP 52097924	A	19770817	JP 1976-14668	19760212 <--
JP 55034792	B	19800909		
AU 7620241	A	19780608	AU 1976-20241	19761203 <--
AU 501137	B2	19790614		
GB 1535435	A	19781213	GB 1976-50453	19761203 <--
US 4131686	A	19781226	US 1976-747898	19761206 <--
NL 7613587	A	19770614	NL 1976-13587	19761207 <--
SE 7613838	A	19770612	SE 1976-13838	19761209 <--
SE 431539	B	19840213		
SE 431539	C	19840524		
BE 849323	A1	19770610	BE 1976-6045790	19761210 <--
DK 7605577	A	19770612	DK 1976-5577	19761210 <--
DK 144417	B	19820308		
DK 144417	C	19820816		
FR 2334345	A1	19770708	FR 1976-37399	19761210 <--
FR 2334345	B1	19781229		
CA 1075264	A1	19800408	CA 1976-267671	19761210 <--
CH 622768	A5	19810430	CH 1976-15586	19761210 <--

PRIORITY APPLN. INFO.: JP 1975-148145 A 19751211
JP 1976-14668 A 19760212
OTHER SOURCE(S): MARPAT 87:134505
AB Oxidation by SeO2 of 2-MeOC6H4COMe gave 2-MeOC6H4COCHO, which gave the Schiff base on treatment with 3,4-(MeO)2C6H3CH2CH2NH2 and was reduced by NaBH4 to give 2-ROC6H4CH(OH)CH2NHCH2CH2C6H3(OMe)2-3,4 (I, R = Me). I (R = Et or Bu) were prepared similarly. I lowered blood sugar concentration, e.g., (-)-I (R = Me) at 1 mg/kg lowered the blood sugar concentration in mice by 26-31%.
IT 62717-79-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(manufacture and hypoglycemic activity of)
RN 62717-79-7 HCAPLUS
CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-2-methoxy- (CA INDEX NAME)



L10 ANSWER 77 OF 77 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1977:439092 HCAPLUS
DOCUMENT NUMBER: 87:39092
ORIGINAL REFERENCE NO.: 87:6155a,6158a
TITLE: Benzyl alcohol derivatives
INVENTOR(S): Ikezaki, Muneyoshi; Ito, Nobuo; Okazaki, Yasushi; Hoshiyama, Masao; Nagao, Taku; Nakajima, Hiromichi
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Ger. Offen., 16 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2542881	A1	19770331	DE 1975-2542881	19750925 <--
DE 2542881	B2	19791018		
DE 2542881	C3	19800703		

PRIORITY APPLN. INFO.: DE 1975-2542881 A 19750925
AB RC6H4CH(OH)CH2NHCH2CH2C6H3(OMe)2-3,4 (I, R = 2-, 3-, 4-OH) were prepared by treating PhCH2OC6H4COCH2Cl with 3,4-(MeO)2C6H3CH2CH2NH2, reducing PhCH2OC6H4COCH2NHCH2CH2C6H3(OMe)2-3,4 with NaBH4, and debenzylating I (R = PhCH2O) with Pd-C. I (R = 3-, 4-OH) stimulated adrenergic β1-receptors. Thus at 8 μg/kg iv. in dogs I (R = 4-OH) caused a 76% increase in heart contractile force and I (R = 3-OH) a 55% increase at

10 μg/kg. I (R = 2-OH) at 10 mg/kg orally in mice caused a 38% decrease in blood sugar level.

IT 59121-15-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antidiabetic activity of)

RN 59121-15-2 HCAPLUS

CN Benzenemethanol, α-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]methyl]-2-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	460.97	648.99
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-63.14	-63.14

FILE 'REGISTRY' ENTERED AT 15:41:02 ON 06 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JAN 2009 HIGHEST RN 1092651-12-1
DICTIONARY FILE UPDATES: 5 JAN 2009 HIGHEST RN 1092651-12-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of

experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\233r.str

L11 STRUCTURE UPLOADED

=> s l11
SAMPLE SEARCH INITIATED 15:42:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 112 TO ITERATE

100.0% PROCESSED 112 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1606 TO 2874
PROJECTED ANSWERS: 0 TO 0

L12 0 SEA SSS SAM L11

=> s l11 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 15:42:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2346 TO ITERATE

100.0% PROCESSED 2346 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L13 1 SEA SSS FUL L11

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 186.84 835.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -63.14

FILE 'HCAPLUS' ENTERED AT 15:42:49 ON 06 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Jan 2009 VOL 150 ISS 2
FILE LAST UPDATED: 5 Jan 2009 (20090105/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l13
L14 1 L13

=> d l14, ibib abs hitstr, 1

L14 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:59050 HCAPLUS
DOCUMENT NUMBER: 148:321816
TITLE: Novel cholesterol biosynthesis inhibitors targeting human lanosterol 14α-demethylase (CYP51)
AUTHOR(S): Korosec, Tina; Acimovic, Jure; Seliskar, Matej; Kocjan, Darko; Tacer, Klementina Fon; Rozman, Damjana; Urleb, Uros
CORPORATE SOURCE: Drug Discovery, Lek Pharmaceuticals d. d., Ljubljana, Verovskova 57, 1000, 57, Slovenia
SOURCE: Bioorganic & Medicinal Chemistry (2008), 16(1), 209-221
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 148:321816
AB Novel cholesterol biosynthesis inhibitors, a group of pyridylethanol(phenylethyl)amine derivs., were synthesized. Sterol profiling assay in the human hepatoma HepG2 cells revealed that compds. target human lanosterol 14α-demethylase (CYP51). Structure-activity relationship study of the binding with the overexpressed human CYP51 indicates that the pyridine binds within the heme binding pocket in an analogy with the azoles.
IT 1010077-09-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel cholesterol biosynthesis inhibitors targeting human lanosterol 14α-demethylase (CYP51))
RN 1010077-09-4 HCAPLUS
CN 3-Pyridinemethanol, α-[[propyl[2-(3-pyridinyl)ethyl]amino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.49	844.32
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.82	-63.96

FILE 'REGISTRY' ENTERED AT 15:43:24 ON 06 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JAN 2009 HIGHEST RN 1092651-12-1
DICTIONARY FILE UPDATES: 5 JAN 2009 HIGHEST RN 1092651-12-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\iop.str

L15 STRUCTURE UPLOADED

=> s l15
SAMPLE SEARCH INITIATED 15:44:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 207 TO ITERATE

100.0% PROCESSED 207 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

```
FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:          3277 TO     5003
PROJECTED ANSWERS:                0 TO        0

L16           0 SEA SSS SAM L15

=> s l15 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 15:44:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     4127 TO ITERATE

100.0% PROCESSED     4127 ITERATIONS                                 5 ANSWERS
SEARCH TIME: 00.00.01

L17           5 SEA SSS FUL L15

=> d his

     (FILE 'HOME' ENTERED AT 15:33:13 ON 06 JAN 2009)

     FILE 'REGISTRY' ENTERED AT 15:33:24 ON 06 JAN 2009
L1               STRUCTURE UPLOADED
L2            44 S L1
L3          3396 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 15:36:19 ON 06 JAN 2009
L4           155 S L3/USES
L5             0 S L4 AND RODE, B?/AU
L6             1 S L4 AND ROZMAN, D?/AU
L7           154 S L4 NOT L6
L8             0 S L7 AND FON TACER, K?/AU
L9             0 S L7 AND KOCJA, D?/AU
L10           77 S L7 AND PD < AUGUST 2002

     FILE 'REGISTRY' ENTERED AT 15:41:02 ON 06 JAN 2009
L11              STRUCTURE UPLOADED
L12            0 S L11
L13            1 S L11 FULL

     FILE 'HCAPLUS' ENTERED AT 15:42:49 ON 06 JAN 2009
L14            1 S L13

     FILE 'REGISTRY' ENTERED AT 15:43:24 ON 06 JAN 2009
L15              STRUCTURE UPLOADED
L16            0 S L15
L17            5 S L15 FULL

=> s l17 not l13
L18            5 L17 NOT L13

=> file hcaplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
```

FULL ESTIMATED COST 186.36 1030.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -63.96

FILE 'HCAPLUS' ENTERED AT 15:44:49 ON 06 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Jan 2009 VOL 150 ISS 2
FILE LAST UPDATED: 5 Jan 2009 (20090105/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l18/uses
             4 L18
       7350115 USES/RL
L19          1 L18/USES
                 (L18 (L) USES/RL)

=> d l19, ibib abs fhitstr, 1
```

L19 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:499574 HCAPLUS
DOCUMENT NUMBER: 148:511800
TITLE: Hydrogen Peroxide and Dioxygen Activation by Dinuclear Copper Complexes in Aqueous Solution: Hydroxyl Radical Production Initiated by Internal Electron Transfer
AUTHOR(S): Zhu, Qing; Lian, Yuxiang; Thyagarajan, Sunita; Rokita, Steven E.; Karlin, Kenneth D.; Blough, Neil V.
CORPORATE SOURCE: Department of Chemistry and Biochemistry, University of Maryland, College Park, MD, 20742, USA
SOURCE: Journal of the American Chemical Society (2008), 130(20), 6304-6305
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal

LANGUAGE: English

AB Dinuclear Cu(II) complexes, CuII2Nn (n = 4 or 5), were recently found to specifically cleave DNA in the presence of a reducing thiol and O2 or in the presence of H2O2 alone. However, CuII2N3 and a closely related mononuclear Cu(II) complex exhibited no selective reaction under either condition. Spectroscopic studies indicate an intermediate is generated from CuII2Nn (n = 4 or 5) and mononuclear Cu(II) solns. in the presence of H2O2 or from CuI2Nn (n = 4 or 5) in the presence of O2. This intermediate decays to generate OH radicals and ligand degradation products at room temperature

The lack of reactivity of the intermediate with a series of added electron donors suggests the intermediate discharges through a rate-limiting intramol. electron transfer from the ligand to the metal peroxo center to produce an OH radical and a ligand-based radical. These results imply that DNA cleavage does not result from direct reaction with a metal-peroxo intermediate but instead arises from reaction with either OH radicals or ligand-based radicals.

IT 1021957-01-6

RL: BSU (Biological study, unclassified); CAT (Catalyst use); FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process); USES (Uses)

(hydrogen peroxide and dioxygen activation by dinuclear copper complexes in aqueous solution and hydroxyl radical production initiated by internal electron transfer)

RN 1021957-01-6 HCAPLUS

CN 2-Pyridinemethanol, α-[[[4-[bis[2-(2-pyridinyl)ethyl]amino]butyl][2-(2-pyridinyl)ethyl]amino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT